Stock Code:3105

# WIN SEMICONDUCTORS CORP. AND SUBSIDIARIES

#### CONSOLIDATED FINANCIAL STATEMENTS

With Independent Auditors' Review Report For the Three Months Ended March 31, 2023 and 2022

Address: No.69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan

Telephone: 886-3-397-5999

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

# **Table of contents**

		Contents	Page				
	1. Cove	er Page	1				
	2. Tabl	e of Contents	2				
	3. Inde	pendent Auditors' Review Report	3				
4. Consolidated Balance Sheets							
	5. Cons	solidated Statement of Comprehensive Income	5				
	6. Cons	solidated Statement of Changes in Equity	6				
	7. Cons	solidated Statement of Cash Flows	7				
	8. Note	s to the Consolidated Financial Statements					
	(1)	Company history	8				
	(2)	Approval date and procedures of the consolidated financial statements	8				
	(3)	New standards, amendments and interpretations adopted	8~10				
	(4)	Summary of significant accounting policies	10~12				
	(5)	Significant accounting assumptions and judgments, and major sources of estimation uncertainty	12~13				
	(6)	Explanation of significant accounts	13~51				
	(7)	Related-party transactions	52				
	(8)	Pledged assets	53				
	(9)	Commitments and contingencies	53				
	(10)	Losses due to major disasters	53				
	(11)	Subsequent events	53				
	(12)	Other	54				
	(13)	Other disclosures					
		(a) Information on significant transactions	$57 \sim 60$				
		(b) Information on investments	61				
		(c) Information on investment in mainland China	62~63				
		(d) Information on major shareholders	63				
	(14)	Segment information	55~56				



# 安侯建業群合會計師重務的 KPMG

台北市110615信義路5段7號68樓(台北101大樓) 68F., TAIPEI 101 TOWER, No. 7, Sec. 5, Xinyi Road, Taipei City 110615, Taiwan (R.O.C.) 電話 Tel + 886 2 8101 6666 傳 真 Fax + 886 2 8101 6667 網 址 Web kpmg.com/tw

#### **Independent Auditors' Review Report**

To the Board of Directors of WIN Semiconductors Corp.:

#### Introduction

We have reviewed the accompanying consolidated balance sheets of WIN Semiconductors Corp. and subsidiaries as of March 31, 2023 and 2022, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2023 and 2022, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standards ("IASs") 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

# **Scope of Review**

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of any significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### Conclusion

Based on our reviews and the review report of another auditor (please refer to Other Matter Paragraph), nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of WIN Semiconductors Corp. and subsidiaries as of March 31, 2023 and 2022, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2023 and 2022 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.



#### Other Matter

We did not review the financial statements for the three months ended March 31, 2022, of certain investments accounted for using the equity method. That financial statements for the three months ended March 31, 2022 were reviewed by another auditor, whose review report has been furnished to us, and our conclusion, insofar as it relates to the amounts included in these investments, is based solely on the review report of another auditor. The investment accounted for using the equity method amounted to \$9,863,647 thousand, constituting 13.32% of consolidated total assets as of March 31, 2022, the related share of profit of associates and joint ventures accounted for using the equity method amounted to \$115,853 thousand, and the related share of other comprehensive income of associates and joint ventures accounted for using the equity method amounted to \$67,559 thousand, constituting 9.99% and 5.82% of consolidated total comprehensive income and loss for the three months ended March 31, 2022, respectively.

The engagement partners on the reviews resulting in this independent auditors' review report are Ya-Ling Chen and Ming-Hung Huang.

#### **KPMG**

Taipei, Taiwan (The Republic of China) May 10, 2023

# Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

#### (English Translation of Consolidated Financial Statements Originally Issued in Chinese)

#### Reviewed only, not audited in accordance with Standards on Auditing as of March 31, 2023 and 2022

#### WIN Semiconductors Corp. and Subsidiaries

## **Consolidated Balance Sheets**

#### March 31, 2023, December 31, and March 31, 2022

(Expressed in Thousands of New Taiwan Dollars)

			March 31, 2023		December 31, 2022		March 31, 2022		_		March 31, 2023		December 31, 2022		March 31, 2022	
	Assets	Amount		<u>/o</u> _	Amount	<u>%</u>	Amount	%		Liabilities and Equity	Amount	%	Amount	%	Amount	%
	Current assets:									Current liabilities:						
1100	Cash and cash equivalents (Note 6(a))	\$ 10,406,1	67	15	10,379,712	15	14,207,296	19	2100	······ · · · · · · · · · · · · ·	\$ 15,957	-	-	-	11,594	-
1110	Current financial assets at fair value through profit or loss (Note 6(b))		56	-	120,845	-	56,557	-	2120	Current financial liabilities at fair value through profit or loss (Notes 6(b) and 6(p))	306,682	. 1	449,261	1	526,099	1
1170	Notes and accounts receivable, net (Notes 6(c) and				04.5.540				2130	Current contract liabilities (Note 6(x))	309,002	1	235,309	-	249,011	-
4240	6(x))	777,5		1	916,640	1	2,019,684	3	2170	Notes and accounts payable	724,935	1	1,016,716	1	1,530,971	2
1310	Inventories (Note 6(e))	5,297,3		8	5,420,476	8	6,294,761	8	2200	Other payables (Notes 6(u) and 6(y))	3,010,200	4	2,497,109	4	8,371,384	12
1400	Current biological assets (Note 6(f))	162,3		-	93,368	-	77,850	-	2280	Current lease liabilities (Notes 6(q) and 6(ad))	108,544	-	103,570	-	123,352	-
1470	Other current assets (Notes 6(d) and 6(m))	254,2		_1 _	282,210	_1	551,510		2321	Bonds payable, current portion (Notes (p) and 6(ad))	10,568,792	15	-	-	-	-
	Total current assets Non-current assets:	17,019,4	21 _2	<u> 25</u>	17,213,251	_25	23,207,658	31	2322	Long-term borrowings, current portion (Notes (o), 6(ad) and 8)	2,473,067	' 4	1,731,147	3	_	_
1510	Non-current financial assets at fair value through								2399	Other current liabilities	220,451		213,976		223,242	_
	profit or loss (Note 6(b))	1,872,7	83	3	1,661,503	2	1,941,159	3	20,,,	Total current liabilities	17,737,630		6,247,088	9		
1517	Non-current financial assets at fair value through other comprehensive income (Note 6(b))	2,196,1	07	3	1,841,932	3	2,097,104	3		Non-current liabilities:	17,757,050				, ,	
1550	Investments accounted for using equity method								2530	Bonds payable (Notes 6(p) and 6(ad))	-	-	10,669,555		13,329,290	
	(Note 6(g))	10,906,1	11 1	16	10,873,014	15	10,582,420	14	2540	Long-term borrowings (Notes 6(o), 6(ad) and 8)	16,168,030	24	15,870,298	23	13,519,589	19
1600	Property, plant and equipment (Notes 6(i) and 8)	31,662,1	71 4	46	31,546,006	46	28,638,396	39	2570	Deferred tax liabilities	4,320	) -	16,185	-	30,184	
1755	Right-of-use assets (Notes 6(j) and 8)	1,075,2	05	1	1,099,729	2	1,243,457	2	2580	Non-current lease liabilities (Notes 6(q) and 6(ad))	904,742	1	924,832	1	1,030,059	1
1760	Investment property (Note 6(k))	1,047,3	03	1	1,048,632	1	1,052,619	1	2600	Other non-current liabilities (Notes 6(s), 6(ad) and 7)	211,282	<u> </u>	210,711		232,442	
1780	Intangible assets (Note 6(l))	557,5	60	1	562,305	1	620,380	1		Total non-current liabilities	17,288,374	25	27,691,581	40	28,141,564	38
1830	Non-current biological assets (Note 6(f))	235,8	16	-	273,554	-	383,660	-		Total liabilities	35,026,004	51	33,938,669	49	39,177,217	53
1840	Deferred tax assets	821,6	15	1	756,114	1	510,891	1		Equity (Notes 6(b), 6(g), 6(h), 6(p), 6(u) and 6(v)):						
1915	Prepayments for business facilities	1,160,7	42	2	1,765,808	3	3,312,267	4	3110	Ordinary shares	4,239,404	6	4,239,404	6	4,239,764	6
1990	Other non-current assets (Notes 6(m) and 8)	559,8	00	1	486,365	1	483,132	1	3200	Capital surplus	9,965,055	14	9,964,088	14	9,970,823	13
	Total non-current assets	52,095,2	13 7	75	51,914,962	75	50,865,485	69	3300	Retained earnings	16,889,749	24	18,351,411	27	17,451,067	24
									3400	Other equity interests	1,194,221	2	773,633	1	1,076,972	1
										Total equity attributable to owners of parent	32,288,429	46	33,328,536	48	32,738,626	44
									36XX	Non-controlling interests	1,800,201	3	1,861,008	3	2,157,300	3
										Total equity	34,088,630	49	35,189,544	51	34,895,926	47
	Total assets	\$ 69,114,6	34 10	00	69,128,213	100	74,073,143	100		Total liabilities and equity	\$ 69,114,634	100	69,128,213	100	74,073,143	100

# (English Translation of Consolidated Financial Statements Originally Issued in Chinese) Reviewed only, not audited in accordance with Standards on Auditing

# WIN Semiconductors Corp. and Subsidiaries

# **Consolidated Statement of Comprehensive Income**

## For the three months ended March 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Common Share)

		For the three mon		months	ended March 3	31
			2023		2022	
			Amount	%	Amount	%
4000	Operating revenue (Notes 6(b), 6(g) and 6(x))	\$	2,859,558	100	5,596,993	100
5000	Operating costs (Notes 6(e), 6(f), 6(i), 6(j), 6(q), 6(s), 6(v), 6(y), 7 and 12)	_	(2,533,460)	(88)	(3,882,832)	<u>(69</u> )
	Gross profit from operating	_	326,098	12	1,714,161	31
	Operating expenses (Notes $6(c)$ , $6(i)$ , $6(j)$ , $6(q)$ , $6(s)$ , $6(v)$ , $6(y)$ , $7$ and $12$ ):					
6100	Selling expenses		(103,845)	(4)	(85,803)	(2)
6200	Administrative expenses		(311,968)	(11)	(365,141)	(6)
6300	Research and development expenses		(504,116)	(18)	(347,006)	(6)
6450	Gains (losses) on expected credit impairment		(922)		7	
	Total operating expenses		(920,851)	(33)	(797,943)	(14)
	Net operating income (loss)		(594,753)	(21)	916,218	17
	Non-operating income and expenses (Notes 6(b), 6(g), 6(i), 6(p), 6(q), 6(z), 6(ad) and 7):					
7100	Interest income		53,944	2	5,414	-
7010	Other income		17,262	1	81,574	1
7020	Other gains and losses		122,445	4	6,602	-
7050	Finance costs		(138,580)	(5)	(80,501)	(1)
7060	Share of profit (loss) of associates and joint ventures accounted for using equity method, net		(15,939)	(1)	61,455	1
	Total non-operating income and expenses		39,132	1	74,544	1
7900	Profit (loss) before tax	_	(555,621)	(20)	990,762	18
7950	Tax benefit (expense) (Note 6(t))		76,998	3	(204,704)	(4)
	Profit (loss)	_	(478,623)	(17)	786,058	14
8300	Other comprehensive income:	_	,			
8310	Components of other comprehensive income that will not be reclassified to profit or loss (Notes 6(g) and 6(u))					
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through					
	other comprehensive income		354,727	13	(84,825)	(1)
8320	Share of other comprehensive income of associates and joint ventures accounted for using equity method that will not be reclassified to profit or loss		-	-	579	-
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	_				
	Total components of other comprehensive income (loss) that will not be reclassified to profit or loss		354,727	13	(84,246)	(1)
8360	Components of other comprehensive income that will be reclassified to profit or loss (Notes 6(g) and 6(u))					
8361	Exchange differences on translation of foreign financial statements		40,797	1	387,707	7
8370	Share of other comprehensive income of associates and joint ventures accounted for using equity		,		Ź	
9200	method that will be reclassified to profit or loss		35,555	1	70,523	1
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss		-	_	-	_
	Total components of other comprehensive income (loss) that will be reclassified to profit	-				
	or loss	_	76,352	2	458,230	8
8300	Other comprehensive income, net		431,079	15	373,984	7
8500	Total comprehensive income	\$_	(47,544)	<u>(2)</u>	1,160,042	21
	Profit (loss) attributable to:	_				
8610	Profit (loss) attributable to owners of parent	\$	(401,811)	(14)	882,221	16
8620	Profit (loss) attributable to non-controlling interests		(76,812)	(3)	(96,163)	(2)
		\$	(478,623)	(17)	786,058	14
	Comprehensive income (loss) attributable to:	=				
8710	Comprehensive income, attributable to owners of parent	\$	18,777	_	1,186,730	21
8720	Comprehensive income (loss), attributable to non-controlling interests		(66,321)	(2)	(26,688)	-
		\$	(47,544)	(2)	1,160,042	21
	Earnings per common share (expressed in New Taiwan dollars) (Note 6(w))	=		<u> </u>	, -,	=
9750	Basic earnings per share	\$	(0.95)		2.08	
9850	Diluted earnings per share	\$	(1.14)		2.07	
		- '=				

# (English Translation of Consolidated Financial Statements Originally Issued in Chinese) Reviewed only, not audited in accordance with Standards on Auditing

WIN Semiconductors Corp. and Subsidiaries

**Consolidated Statement of Changes in Equity** 

For the three months ended March 31, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

	Equity attributable to owners of parent												
	Other equity interests												
								Unrealized					
								gains					
					Retained earnings		Exchange	(losses) on financial assets	Other				
					Retained carnings		differences on	measured at	unearned				
							translation of	fair value	compensation		Total equity		
						Total	foreign	through other	for restricted		attributable to		
		Ordinary	Capital		Unappropriated	retained	financial	comprehensive	shares of	Total other		Non-controlling	
	_	shares	surplus		retained earnings	earnings	statements	income	employees	equity interests	parent	interests	Total equity
Balance at January 1, 2022	\$_	4,239,764	9,969,914	3,172,722	16,787,543	19,960,265	(269,409)	1,044,071	(6,597)	768,065	34,938,008	2,183,988	37,121,996
Appropriation and distribution of retained earnings:					(2.201.011)	(2.201.011)							
Cash dividends of ordinary shares	_				(3,391,811)	(3,391,811)					(3,391,811)		(3,391,811)
Profit (losses) for the three months ended March 31, 2022		-	-	-	882,221	882,221	-	-	-	-	882,221	(96,163)	786,058
Other comprehensive income for the three months ended March 31, 2022	_				-	-	388,755	(84,246)		304,509	304,509	69,475	373,984
Total comprehensive income for the three months ended March 31, 2022	_				882,221	882,221	388,755	(84,246)		304,509	1,186,730	(26,688)	1,160,042
Compensation cost arising from restricted shares of employees		-	-	-	- 202	- 202	-	-	4,398	4,398	4,398	-	4,398
Changes in equity of associates accounted for using equity method	_	- 4 220 #64	909		392	392	- 110.246		- (2.100)		1,301		1,301
Balance at March 31, 2022	\$_	4,239,764	9,970,823	3,172,722	14,278,345	17,451,067	119,346	959,825	(2,199)		32,738,626	2,157,300	34,895,926
Balance at January 1, 2023	\$_	4,239,404	9,964,088	3,892,688	14,458,723	18,351,411	61,004	712,629		773,633	33,328,536	1,861,008	35,189,544
Appropriation and distribution of retained earnings:													
Cash dividends of ordinary shares	_				(1,059,851)	(1,059,851)					(1,059,851)		(1,059,851)
Losses for the three months ended March 31, 2023		-	-	-	(401,811)	(401,811)		-	-	-	(401,811)		(478,623)
Other comprehensive income for the three months ended March 31, 2023	_						65,861	354,727		420,588	420,588	10,491	431,079
Total comprehensive income for the three months ended March 31, 2023	_				(401,811)	(401,811)	65,861	354,727		420,588	18,777	(66,321)	(47,544)
Changes in equity of associates accounted for using equity method		-	967	-	-	-	-	-	-	-	967	-	967
Stock option compensation cost of subsidiary	_											5,514	5,514
Balance at March 31, 2023	\$_	4,239,404	9,965,055	3,892,688	12,997,061	16,889,749	126,865	1,067,356		1,194,221	32,288,429	1,800,201	34,088,630

# (English Translation of Consolidated Financial Statements Originally Issued in Chinese) <u>Reviewed only, not audited in accordance with Standards on Auditing</u>

## WIN Semiconductors Corp. and Subsidiaries

## **Consolidated Statement of Cash Flows**

## For the three months ended March 31, 2023 and 2022

## (Expressed in Thousands of New Taiwan Dollars)

	For the three months ended March 31 2023 2022				
Cash flows from (used in) operating activities:	Φ.	(555, 621)	000.762		
(Loss) profit before tax	\$	(555,621)	990,762		
Adjustments: Adjustments to reconcile profit (loss):					
Depreciation expense		1,077,185	1.057.776		
Amortization expense		29,444	36,328		
Loss on (reversal of) expected credit impairment		922	(7)		
Net (gains) losses on financial assets or liabilities at fair value through profit or loss		(340,267)	274,087		
Interest expense		138,580	80,501		
Interest income		(53,944)	(5,414)		
Dividend income		(17,293)	(81,056)		
Share-based payments		5,514	4,398		
Share of profit of associates and joint ventures accounted for using equity method		(3,035)	(81,878)		
Losses on disposal of property, plant and equipment		22,826	142		
Prepayments for business facilities transferred to expenses		- 14.500	35		
Changes in biological assets at fair value		14,520	41,166		
Unrealized foreign exchange gains		(83,446)	(16,273)		
Gains on repurchases of bonds payable  Losses on lease modification		(15,316)	21.721		
Total adjustments to reconcile profit (loss)		775,690	21,721 1,331,526		
Changes in operating assets and liabilities:		773,090	1,331,320		
Changes in operating assets and habitudes.  Changes in operating assets:					
Decrease in financial assets at fair value through profit or loss		14,500	1,000		
Decrease in notes and accounts receivable		138,176	697,883		
Decrease in inventories		122,903	252,473		
(Increase) decrease in biological assets		(72,197)	21,677		
Decrease (increase) in other current assets		23,676	(16,707)		
Total changes in operating assets		227,058	956,326		
Changes in operating liabilities:					
Increase (decrease) in contract liabilities		73,693	(104,146)		
Decrease in notes and accounts payable		(291,781)	(631,854)		
Decrease in other payables		(657,474)	(668,067)		
Increase in other current liabilities		6,475	46,337		
Increase in other non-current liabilities		523	39		
Total changes in operating liabilities		(868,564)	(1,357,691)		
Total changes in operating assets and liabilities		(641,506)	(401,365)		
Cash flows (used in) generated from operations		(421,437)	1,920,923		
Dividends received		10,543	8,745		
Income taxes paid  Net cash flows (used in) from operating activities		(30,539) (441,433)	(1,813) 1,927,855		
Cash flows from (used in) investing activities:		(441,433)	1,927,833		
Proceeds from capital reduction of financial assets at fair value through other comprehensive income		_	5,667		
Acquisition of financial assets at fair value through profit or loss		(15,490)	(45,162)		
Proceeds from disposal of financial assets at fair value through profit or loss		-	9,969		
Proceeds from capital reduction of financial assets at fair value through profit or loss		2,208	5,389		
Acquisition of investments accounted for using equity method		(14,498)	-		
Acquisition of property, plant and equipment		(489,317)	(975,495)		
Proceeds from disposal of property, plant and equipment		209	- '		
Acquisition of intangible assets		(34,349)	(18,507)		
Increase in other non-current assets		(73,471)	(162,732)		
Increase in prepayments for business facilities		(46,966)	(344,307)		
Interest received		49,211	6,038		
Dividends received		6,750	72,311		
Net cash flows used in investing activities		(615,713)	(1,446,829)		
Cash flows from (used in) financing activities:					
Increase in short-term loans		15,957	11,594		
Proceeds from long-term debt		1,679,764	1,453,200		
Repayments of long-term debt		(590,000)	(4,123,113		
Repayments of lease liabilities		(19,259)	(27,389)		
Increase (decrease) in other non-current liabilities		(12.248)	(11,021)		
Interest paid  Net cash flows from (used in) financing activities		(13,248) 1,073,262	(32,568)		
Effect of exchange rate changes on cash and cash equivalents		10,339	123,808		
Net increase (decrease) in cash and cash equivalents		26,455	(2,124,463		
Cash and cash equivalents at beginning of period		10,379,712	16,331,759		
		10,406,167	14,207,296		

# (English Translation of Consolidated Financial Statements Originally Issued in Chinese) Reviewed only, not audited in accordance with Standards on Auditing as of March 31, 2023 and 2022

# WIN Semiconductors Corp. and Subsidiaries

### **Notes to the Consolidated Financial Statements**

March 31, 2023 and 2022

# (Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

# (1) Company history:

WIN Semiconductors Corp. (the "Company") was incorporated on October 16, 1999 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is No. 69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan.

The main operations of the Company and its subsidiaries (together referred to as "the Group") are as follows:

- (a) Researching, developing, manufacturing, and selling of GaAs wafers.
- (b) Developing hog farming technology and trading.
- (c) Researching, manufacturing and selling of high-density gene chips, biochip optical readers, microelectrophoresis analyzers and diagnostic tool for endometrial cancer.

#### (2) Approval date and procedures of the consolidated financial statements:

These consolidated financial statements was authorized for issue by the Board of Directors as of May 10, 2023.

# (3) New standards, amendments and interpretations adopted:

(a) The impact of the International Financial Reporting Standards ("IFRSs") endorsed by the Financial Supervisory Commission, R.O.C. ("FSC") which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2023:

- Amendments to IAS 1 "Disclosure of Accounting Policies"
- Amendments to IAS 8 "Definition of Accounting Estimates"
- Amendments to IAS 12 "Deferred Tax related to Assets and Liabilities arising from a Single Transaction"

# (b) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations  Amendments to IAS 1  "Classification of Liabilities as Current or Non-current"	Content of amendment Under existing IAS 1 requirements, companies classify a liability as current when they do not have an unconditional right to defer settlement for at least 12 months after the reporting date. The amendments has removed the requirement for a right to be unconditional and instead now requires that a right to defer settlement must exist at the reporting date and have substance.	Effective date per IASB January 1, 2024
	The amendments clarify how a company classifies a liability that can be settled in its own shares – e.g. convertible debt.	
Amendments to IAS 1 "Non- current Liabilities with Covenants"	After reconsidering certain aspects of the 2020 amendments1, new IAS 1 amendments clarify that only covenants with which a company must comply on or before the reporting date affect the classification of a liability as current or non-current.	January 1, 2024
	Covenants with which the company must comply after the reporting date (i.e. future covenants) do not affect a liability's classification at that date. However, when non-current liabilities are subject to future covenants, companies will now need to disclose information to help users understand the risk that those liabilities could become repayable within 12 months after the reporting date.	

The Group is evaluating the impact of its initial adoption of the abovementioned standards or interpretations on its consolidated financial position and consolidated financial performance. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture"
- IFRS 17 "Insurance Contracts" and its amendments
- Amendments to IFRS 17 "Initial Application of IFRS 17 and IFRS 9 Comparative Information "
- Amendments to IFRS16 "Requirements for Sale and Leaseback Transactions"

# (4) Summary of significant accounting policies:

Except the following accounting policies mentioned below, the significant accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2022. For the related information, please refer to Note 4 of the consolidated financial statements for the year ended December 31, 2022.

#### (a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 "Interim Financial Reporting" which are endorsed by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed by the FSC (hereinafter referred to IFRS endorsed by the FSC) for a complete set of the annual consolidated financial statements.

#### (b) Basis of consolidation

# (i) List of subsidiaries in the consolidated financial statements:

			Shareholding			
			March 31,	December 31,	March 31,	
Name of investor	Name of subsidiary	Principal activity	2023	2022	2022	Remark
The Company	WIN SEMI. USA, INC.	Marketing	100.00 %	100.00 %	100.00 %	
The Company	Win Semiconductors Cayman Islands Co., Ltd. (abbrev. Win Cayman)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Venture Capital Corp. (abbrev. WVC)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	Phalanx Biotech Group, Inc. (abbrev. PBL)	Researching, manufacturing and selling of high-density gene chips and testing service	73.67 %	73.67 %	73.67 %	
The Company	WIN Earn Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Chance Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
WVC	Phalanx Biotech Group, Inc.	Researching, manufacturing and selling of high-density gene chips and testing service	1.54 %	1.54 %	1.54 %	
Win Cayman	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. (abbrev. Chainwin Cayman)	Investment activities	81.23 %	81.23 %	81.23 %	
Chainwin Cayman	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Chance Agriculture Development Co., Ltd. (abbrev. Jiangsu Win Chance)	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. (abbrev. Jiangsu Chainwin)	Farm feed development and trading	100.00 %	100.00 %	100.00 %	

				Shareholding		
			March 31,	December 31,	March 31,	
Name of investor	Name of subsidiary	Principal activity	2023	2022	2022	Remark
Chainwin Cayman	Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Yield Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	i-Chainwin Technology (Cayman Islands) Co., Ltd.	Investment activities	-	100.00 %	100.00 %	(Note 2)
Chainwin Cayman	Win Lux Biotech (Cayman Islands) Co., Ltd.	Investment activities	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Shine Agriculture Development Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	i-Chainwin Technology Co., Ltd.	Information software services	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech Co., Ltd.	Biotechnology service and pharmaceutical testing	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Sunlight Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Chainwin (Huaian) AloT Co., Ltd.	Information software services	-	100.00 %	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Advane Bio-Assay Co., Ltd.	Biotechnology testing service	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and bioassay	100.00 %	100.00 %	100.00 %	
Jiangsu Win Chance	Jiangsu Win Wonder Agriculture Development Co., Ltd.	Developing farming technology and trading	100.00 %	100.00 %	100.00 %	
Jiangsu Win Chance	Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Chainwin (Huaian) AloT Co., Ltd.	Information software services	100.00 %	-	-	(Note 1)
PBL	PhalanxBio, Inc.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	
PBL	Phalanx Biotech Limited. (abbrev. PBL (HK))	Investment activities	100.00 %	100.00 %	100.00 %	
PBL	Guzip Biomarkers Corporation	Developing and selling of diagnostic tool for endometrial cancer	100.00 %	100.00 %	100.00 %	
PBL (HK)	Onearray Biotech (Kunshan) Co., Ltd.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	

Note 1: Changes in organizational structure.

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

# (c) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-time events.

Note 2: The liquidation process is completed in the 1st quarter of 2023.

Note 3: The aforementioned subsidiaries were recognized based on the reviewed financial statements by the certified public accountant.

# (d) Income taxes

The income tax expenses have been evaluated and disclosed in accordance with paragraph B12 of IAS 34 "Interim Financial Reporting."

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period by the effective annual tax rate as forecasted by the management. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

#### (5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IFRSs (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Significant accounting estimates and assumptions made by the management may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. The Group has considered the economic implications of climate change on critical accounting estimates and will continue evaluating the impact on its financial position and financial performance.

Except for the following, the preparation of the consolidated financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2022. For the related information, please refer to Note 5 of the consolidated financial statements for the year ended December 31, 2022.

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements is as follows:

#### (a) Judgment of whether the Group has substantive control over its investee

The Group holds 49% of the outstanding voting shares of Rainbow Star Group Limited and is the single largest shareholder of the investee. The remaining 51% of Rainbow Star Group Limited's shares are concentrated within specific shareholders, and therefore the Group cannot obtain more than half of the total number of Rainbow Star Group Limited directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over Rainbow Star Group Limited.

The Group holds 23.79% of the outstanding voting shares of ITEQ Corporation (hereinafter referred to as "ITEQ") and is the single largest shareholder of the investee. Although the remaining 76.21% of ITEQ's shares are not concentrated within specific shareholders, the Group still cannot obtain more than half of the total number of ITEQ directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over ITEO.

# (b) Judgment of whether the Group has significant influence on its investee

The Group's 32.88% shares in NFC Fund II L.P. is deemed as a mutual fund. The Group does not act as the director and is not designed as the representative of those charged with the governance of NFC Fund II L.P. As a result, it is determined that the Group does not have significant influence on NFC Fund II L.P.

#### (6) Explanation of significant accounts:

Except for the following disclosure, the significant account disclosure in the consolidated financial statements for the three months ended March 31, 2023, which compare with the consolidated financial statements for the year ended December 31, 2022, was not changed significantly. For the related information, please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2022.

## (a) Cash and cash equivalents

	rch 31, 2023	December 31, 2022	March 31, 2022
Cash on hand	\$ 230	230	279
Cash in bank	7,053,986	7,022,482	12,906,817
Time deposits	 3,351,951	3,357,000	1,300,200
	\$ 10,406,167	10,379,712	14,207,296

Please refer to Note 6(aa) for the currency risk and sensitivity analysis of the financial assets and liabilities of the Group.

#### (b) Financial instruments

#### (i) Financial assets and liabilities at fair value through profit or loss:

		March 31, 2023	December 31, 2022	March 31, 2022
Mandatorily measured at financial assets at fair value through profit or loss:				
Non-derivative financial assets				
Publicly traded stocks (Note)	\$	482,729	301,109	14,197
Non-public stocks (Note)		-	-	398,433
Money market funds		111,617	111,296	42,360
Private fund (Note)	_	1,400,193	1,369,943	1,542,726
Total	\$_	1,994,539	1,782,348	1,997,716
Current	\$	121,756	120,845	56,557
Non-current	_	1,872,783	1,661,503	1,941,159
	<b>\$</b> _	1,994,539	1,782,348	1,997,716

(Continued)

Note: As of March 31, 2023, December 31 and March 31, 2022, part of the private fund, publicly traded stocks, and non-public stocks were during the lock-up period.

	M	larch 31, 2023	December 31, 2022	March 31, 2022
Mandatorily measured at current financial liabilities at fair value through profit or loss				
Convertible bonds with embedded derivatives	\$	306,682	449,261	526,099

The derivative financial instruments arose from the issuance of overseas convertible bonds of the Group disclosed in Note 6(p).

Refer to Note 6(z) for the amount of re-measurement at fair value recognized in profit or loss.

(ii) Non-current financial assets at fair value through other comprehensive income (FVOCI):

	March 31,		December 31,	March 31,
	2023		2022	2022
Stocks listed on domestic markets	\$	82,524	73,796	93,633
Stocks listed on US markets		1,465,117	1,287,816	1,352,080
Non-public stocks	-	648,466	480,320	651,391
	\$	2,196,107	1,841,932	2,097,104

The Group decided to hold these equity instruments, which are not held for trading, at fair value through other comprehensive income.

For the three months ended March 31, 2023 and 2022, there were no disposals of equity investments at fair value through other comprehensive income, and the gains and losses accumulated in other equity were not transferred to retained earnings during the period.

For the three months ended March 31, 2023 and 2022, the Group received dividend income \$12,236 thousand and \$10,597 thousand, respectively, of the equity investment designated at fair value though other comprehensive income.

## (iii) Sensitivity analysis in the equity price risk:

If the equity price changes, the impact to comprehensive income, using the sensitivity analysis based on the same variables except for the price index for both periods, will be as follows:

	For the three months ended March 31, 2023		For the three mo March 31,	
Prices of securities at the reporting date	After-tax other comprehensive income	After-tax profit (loss)	After-tax other comprehensive income	After-tax profit (loss)
Increasing 3%	\$ 65,883	14,482	62,913	12,379
Decreasing 3%	\$ (65,883)	(14,482)	(62,913)	(12,379)

(iv) As of March 31, 2023, December 31 and March 31, 2022, the financial assets were not pledged. For information on the Group's credit risk, currency risk, and fair value information was disclosed in Note 6(aa).

#### (c) Notes and accounts receivable, net

	M	arch 31, 2023	December 31, 2022	March 31, 2022
Notes receivable	\$	839	1,310	965
Accounts receivable		778,610	916,315	2,019,517
Less: loss allowance		(1,928)	(985)	(798)
	\$	777,521	916,640	2,019,684

The Group applies the simplified approach to provide for its loss allowance used for expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and days past due, as well as incorporate forward looking information.

The loss allowance provision was determined as follows:

# (i) The segment of foundry and agriculture technology:

	March 31, 2023				
			Weighted-	Lifetime	
	Gro	ss carrying	average expected	expected credit	
		amount	loss rate	loss allowance	
Not past due	\$	734,368	0%	-	
Past due 1~60 days		35,600	0%	-	
Past due 61~120 days		2,436	0%	-	
Past due 121~180 days		-	1.02%~4.35%	-	
Past due more than 181 days		1,155	100%	1,155	
	\$	773,559		1,155	

	<b>December 31, 2022</b>				
		ss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance	
Not past due	\$	857,657	0%	-	
Past due 1~60 days		49,028	0%	-	
Past due 61~120 days		1,165	0%	-	
Past due 121~180 days		2,636	0%~3.33%	-	
Past due more than 181 days		_	100%		
	\$	910,486			
			March 31, 2022		
		ss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance	
Not past due	\$	1,931,188	0%		
Past due 1~60 days		83,182	0%	-	
Past due 61~120 days		91	0%	-	
Past due 121~180 days		-	0%~1.67%	-	
Past due more than 181 days			100%		
	\$	2,014,461			

# (ii) The segment of gene chip testing service:

	<b>March 31, 2023</b>				
		ss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance	
Not past due	\$	3,972	0%~2.64%	1	
Past due 1~60 days		988	0%~7.57%	6	
Past due 61~120 days		176	0%~15.58%	15	
Past due 121~180 days		4	0%~44.44%	1	
Past due more than 181 days		750	100%	750	
	\$	5,890		773	

	<b>December 31, 2022</b>				
	Gross carrying amount		Weighted- average expected loss rate	Lifetime expected credit loss allowance	
Not past due	\$	5,177	0%~0.35%	100	
Past due 1~60 days		1,212	0%~7.26%	135	
Past due 61~120 days		-	0%~19.44%	-	
Past due 121~180 days		-	0%~47.22%	-	
Past due more than 181 days		750	100%	750	
	\$	7,139		985	
			March 31, 2022		
		ss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance	
Not past due	\$	3,875	0%~5.13%	3	
Past due 1~60 days		1,195	0%~30.12%	24	
Past due 61~120 days		135	0%~41.48%	4	
Past due 121~180 days		66	0%~55.56%	17	
Past due more than 181 days		750	100%	750	
	\$	6,021		<u>798</u>	
The movements of loss allowance we	ere as follow	s:			
			For the three	For the three	

months ended months ended March 31, 2023 March 31, 2022 Beginning balance 985

Impairment losses recognized (reversed) 922 (7) Effect of changes in foreign exchange rates 21 1,928 <u>798</u> Ending balance

As of March 31, 2023, December 31 and March 31, 2022, the notes and accounts receivable were not discounted nor pledged.

805

# (d) Other receivables (recognized as other current assets)

		March 31, 2023	December 31, 2022	March 31, 2022	
Other receivables	\$	42,076	56,976	35,090	
Less: loss allowance	_	_			
	\$_	42,076	56,976	35,090	

As of March 31, 2023, December 31 and March 31, 2022, other receivables were not past due nor impaired.

The information on the Group's credit risk was disclosed in Note 6(aa).

# (e) Inventories

	March 31, 2023		December 31, 2022	March 31, 2022
Raw materials, supplies and spare parts	\$	4,177,392	4,377,047	4,328,782
Work in process		657,805	562,405	873,970
Finished goods	_	462,154	481,024	1,092,009
	\$_	5,297,351	5,420,476	6,294,761

Except for cost of goods sold and inventories recognized as expenses, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	For the three months ended			
	Mar	ch 31, 2023	March 31, 2022	
Losses on valuation of inventories and obsolescence	<u>\$</u>	110,018	72,454	
Unallocated overheads	\$	17,531	88,205	
Revenue from sale of scraps	\$	(6,758)	(13,903)	
Losses (gains) on physical inventory count	\$	2,076	(4,293)	

As of March 31, 2023, December 31 and March 31, 2022, the inventories were not pledged.

# (f) Biological assets

# (i) List of biological assets:

	Marci 20		December 31, 2022	March 31, 2022
Consumable biological assets	<b>\$</b> _	162,331	93,368	77,850
Bearer biological assets	\$	235,816	273,554	383,660

# (ii) Movements in biological assets:

		the three oths ended ch 31, 2023	For the three months ended March 31, 2022	
Beginning balance	\$	366,922	528,446	
Increase due to purchase		-	25,441	
Input costs		218,117	195,583	
Depreciation expenses		(28,323)	(22,029)	
Decrease due to sales and disposals		(145,920)	(242,701)	
Changes in fair value less costs to sell due to price change	es	(14,520)	(41,166)	
Effect of changes in foreign exchange rates		1,871	17,936	
Ending balance	\$	398,147	461,510	
Current	\$	162,331	77,850	
Non-current		235,816	383,660	
	\$	398,147	461,510	

For the three months ended March 31, 2023 and 2022, the losses of \$14,520 thousand and \$41,166 thousand, respectively, were recognized as operating costs of the consolidated statement of comprehensive income as a result of the remeasurement of biological assets at the higher of its carrying amount or fair value less costs to sell.

### (iii) The numbers of the Group's biological assets were as follows:

Unit: head

	March 31, 2023	December 31, 2022	March 31, 2022
Farrows, hogs and breeders	45,101	49,624	46,725

#### (iv) Fair value

There were no significant addition regarding the fair value of the Group's biological assets. For the related information, please refer to Note 6(f) of the consolidated financial statements for the year ended December 31, 2022.

(v) As of March 31, 2023, December 31 and March 31, 2022, the biological assets were not pledged.

# (g) Investments accounted for using equity method

The components of investments accounted for using the equity method at the reporting date were as follows:

	March 31,	December 31,	March 31,
	2023	2022	2022
Associates	\$ 10,906,111	10,873,014	10,582,420

## (i) Associates

Associates which are material to the Group consisted of the followings:

		Main Operating Location/ Registered	Proportion of Shareholding and Voting Rights		0
Name of Associates	Main Businesses and Products	Country of the Company	March 31, 2023	December 31, 2022	March 31, 2022
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev. Jiangsu CM/Chainwin)	Developing hog farming technology and trading	<del></del> -	49 %	49 %	49 %
ITEQ Corporation (abbrev. ITEQ)	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	Taiwan	23.79 %	23.79 %	20.80 %

The fair value of significant associate listed on the Taiwan Stock Exchange Corporation (TWSE) which is material to the Group is as follows:

	N	March 31, 2023	December 31, 2022	March 31, 2022
ITEQ	\$	6,760,518	6,268,373	9,557,067

The following consolidated financial information of significant associates has been adjusted according to individually prepared IFRS financial statements of these associates.

# 1) The consolidated financial information of Jiangsu CM/Chainwin:

	N	March 31, 2023	December 31, 2022	March 31, 2022	
Current assets	\$	285,097	271,588	208,801	
Non-current assets		1,155,254	1,230,657	1,324,450	
Current liabilities		(72,002)	(72,676)	(141,887)	
Non-current liabilities		(30,068)	(30,026)	(33,150)	
Net assets	\$	1,338,281	1,399,543	1,358,214	

				mo	or the three onths ended rch 31, 2023	For the three months ended March 31, 2022	
	Operating revenue			\$	229,376	96,633	
	Losses			\$	(68,700)	(68,760)	
	Other comprehensive income				_		
	Total comprehensive income (loss)	)		\$	(68,700)	(68,760)	
				mo	or the three onths ended rch 31, 2023	For the three months ended March 31, 2022	
	Carrying amount of equity of Jiang attributable to the Group at the b			\$	684,221	673,302	
	Losses attributable to the Group				(33,663)	(33,693)	
	Exchange differences on translation of foreign financial statements attributable to the Group				9,642	3,543	
	Shares of net assets of Jiangsu CM/Chainwin at the end				660,200	643,152	
	Add: Effect of changes in foreign e	exchan	ge rates		(5,984)	20,923	
	Carrying amount of equity of Jiang attributable to the Group at the e		I/Chainwin	\$ <u></u>	654,216	664,075	
2)	The consolidated financial informa	ition o	f ITEQ:				
			March 31, 2023	De	ecember 31, 2022	March 31, 2022	
	Current assets	\$	21,478,590		21,468,941	24,797,178	
	Non-current assets		12,075,808		11,914,668	10,816,735	
	Current liabilities		(11,102,363)	)	(10,883,035)	(14,158,527)	
	Non-current liabilities	-	(3,252,067	)	(2,389,588)	(671,531)	
	Net assets	\$	19,199,968	=	20,110,986	20,783,855	
				mo	or the three onths ended rch 31, 2023	For the three months ended March 31, 2022	
	Operating revenue			\$	6,259,655	8,269,058	
	Profit			\$	73,983	809,113	
	Other comprehensive income				99,991	570,653	
	Total comprehensive income			\$	173,974	1,379,766	

	For the three months ended March 31, 2023		For the three months ended March 31, 2022	
Carrying amount of equity of ITEQ attributable to the Group at the beginning	\$	10,143,903	9,678,934	
Profit attributable to the Group		23,396	115,853	
Comprehensive income attributable to the Group		25,913	67,559	
Changes in retained earnings of associates		-	392	
Changes in capital surplus of associates	_	967	909	
Carrying amount of equity of ITEQ attributable to the				
Group at the end		10,194,179	9,863,647	
Less: Goodwill		(5,359,849)	(5,245,224)	
Shares of net assets of ITEQ at the end	\$_	4,834,330	4,618,423	

Summary of financial information for the individually insignificant investments in associates accounted for using equity method were as follows. The aforementioned financial information was included in the consolidated financial statements of the Group:

	March 31, 2023	December 31, 2022	March 31, 2022
Total equity of the individually insignificant investments in associates	\$57,716	44,89	54,698
		For the three months ended March 31, 2023	For the three months ended March 31, 2022
Attributable to the Group:			
Profit (losses)		\$ 13,302	$2 \qquad (282)$
Other comprehensive income			
Total comprehensive income (loss)		\$ 13,302	(282)

# (ii) Pledge to secure

As of March 31, 2023, December 31 and March 31, 2022, the investments accounted for using equity method were not pledged.

## (h) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

		Percentage of non-controlling interests				
	D : ( /	March 31,	December 31,	March 31,		
<b>Subsidiaries</b>	<b>Registration</b>	2023	2022	2022		
Chainwin Cayman	Cayman Islands	18.77 %	18.77 %	18.77 %		

The following information of the aforementioned subsidiaries have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in the information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date. Intergroup transactions were not eliminated in this information.

		March 31, 2023	December 31, 2022	March 31, 2022
Current assets	\$	3,853,385	3,110,612	3,756,024
Non-current assets		13,691,154	13,667,133	13,384,979
Current liabilities		(449,392)	(381,345)	(416,462)
Non-current liabilities	_	(8,267,608)	(7,273,176)	(6,082,837)
Net assets	\$_	8,827,539	9,123,224	10,641,704
Non-controlling interests	\$_	1,657,249	1,712,759	1,997,833
			For the three months ended March 31, 2023	For the three months ended March 31, 2022
Operating revenue			\$ 110,438	47,589
Losses			\$ (351,556	) (463,512)
Other comprehensive income			55,871	369,925
Total comprehensive income (loss)			\$ (295,685	(93,587)
Losses attributable to non-controlling interests			\$ (66,000	(87,018)
Comprehensive income (loss), attributable to non-controlling interests			\$ <u>(55,511</u>	(17,570)
			For the three months ended March 31, 2023	For the three months ended March 31, 2022
Net cash flows used in operating activities			\$ (113,818	(312,915)
Net cash flows used in investing activities			(159,808	(849,534)
Net cash flows from (used in) financing activiti	es		1,014,147	(47,541)
Effect of changes in foreign exchange rate			(45,954	(18,866)
Increase (decrease) in cash and cash equivalent	S		\$ 694,567	(1,228,856)

# (i) Property, plant and equipment

The movements in property, plant and equipment were as follows:

		Land	Buildings and structures	Machinery and equipment	Factory and equipment	Other equipment	Construction in progress and inspection- awaited devices	Total
Cost:	_	Lanu	structures	equipment	сцириси	equipment	ucvices	Total
Balance as of January 1, 2023	\$	2,546,534	9,478,472	17,648,311	6,689,192	668,701	9,406,592	46,437,802
Additions		-	2,885	141,136	13,777	8,193	279,506	445,497
Reclassification (Note 1)		-	1,582,325	2,018,450	143,876	14,902	(3,108,593)	650,960
Disposals		-	(15,076)	(1,152,041)	(500,600)	(96,267)	-	(1,763,984)
Effect of changes in foreign exchange rates	_	-	51,718	590	3,519	554	8,066	64,447
Balance as of March 31, 2023	\$	2,546,534	11,100,324	18,656,446	6,349,764	596,083	6,585,571	45,834,722
Balance as of January 1, 2022	\$	2,546,534	5,409,451	20,272,516	6,406,045	565,461	9,402,246	44,602,253
Additions		-	-	74,525	89,646	33,510	1,218,511	1,416,192
Reclassification (Note 2)		-	-	35,649	5,778	5,475	(10,407)	36,495
Disposals		-	(703)	(269,929)	(75,550)	(8,143)	-	(354,325)
Effect of changes in foreign exchange rates	_		99,559	381	1,953	2,933	303,404	408,230
Balance as of March 31, 2022	\$_	2,546,534	5,508,307	20,113,142	6,427,872	599,236	10,913,754	46,108,845
Accumulated depreciation:								
Balance as of January 1, 2023	\$	-	1,193,693	10,327,673	3,073,301	297,129	-	14,891,796
Depreciation		-	121,871	699,160	157,676	42,076	-	1,020,783
Disposals		-	(15,076)	(1,151,300)	(500,600)	(73,973)	-	(1,740,949)
Effect of changes in foreign exchange rates	_		583	(2)	113	227		921
Balance as of March 31, 2023	\$_		1,301,071	9,875,531	2,730,490	265,459		14,172,551
Balance as of January 1, 2022	\$	-	1,045,218	12,327,474	3,213,613	231,951	-	16,818,256
Depreciation		-	65,934	750,981	144,642	40,870	-	1,002,427
Disposals		-	(677)	(269,813)	(75,550)	(8,143)	-	(354,183)
Effect of changes in foreign exchange rates	_		1,669	200	892	1,188		3,949
Balance as of March 31, 2022	\$		1,112,144	12,808,842	3,283,597	265,866		17,470,449
Carrying amount:								
Balance as of January 1, 2023	\$_	2,546,534	8,284,779	7,320,638	3,615,891	371,572	9,406,592	31,546,006
Balance as of March 31, 2023	\$	2,546,534	9,799,253	8,780,915	3,619,274	330,624	6,585,571	31,662,171
Balance as of January 1, 2022	\$	2,546,534	4,364,233	7,945,042	3,192,432	333,510	9,402,246	27,783,997
Balance as of March 31, 2022	\$_	2,546,534	4,396,163	7,304,300	3,144,275	333,370	10,913,754	28,638,396

Note 1: Inventories and prepayments for business facilities were reclassified as property, plant and equipment.

# (i) Pledge to secure

As of March 31, 2023, December 31 and March 31, 2022, the property, plant and equipment were subject to a registered debenture to secured bank loans and line of credit, the collateral for these long-term borrowings was disclosed in Note 8.

Note 2: Prepayments for business facilities and capitalized right-of-use depreciation expenses were reclassified as property, plant and equipment.

# (ii) Property, plant and equipment under construction

The Group rented some pieces of land and entered into different agreements for the construction of its new factories on the said lands. For the three months ended March 31, 2023, the Group has constructed factories amounting to \$354,299 thousand, and has recognized as construction in progress. As of March 31, 2023, the total amount of the construction was \$5,207,421 thousand, and was recognized as construction in progress.

(iii) For the three months ended March 31, 2023 and 2022, capitalized interest expenses amounted to \$50,954 thousand and \$14,966 thousand, respectively. The annual interest rates at which these interest expenses were capitalized ranged from 1.14%~5.76% and 0.57%~0.84%, respectively.

#### (i) Right-of-use assets

The movements in right-of-use assets were as follows:

		Land	Buildings and structures	Other equipment	Total
Cost:					
Balance as of January 1, 2023	\$	881,493	474,148	21,021	1,376,662
Additions		-	-	278	278
Disposals		-	-	(534)	(534)
Effect of change in foreign exchange rates	_	2,086	233	20	2,339
Balance as of March 31, 2023	\$_	883,579	474,381	20,785	1,378,745
Balance as of January 1, 2022	\$	986,869	482,647	20,853	1,490,369
Additions		51,003	82,924	1	133,928
Disposals		(137,947)	(26,980)	(762)	(165,689)
Effect of change in foreign exchange rates	_	16,407	3,363	130	19,900
Balance as of March 31, 2022	\$_	916,332	541,954	20,222	1,478,508
Accumulated depreciation:		_			
Balance as of January 1, 2023	\$	133,545	132,395	10,993	276,933
Depreciation		14,280	10,940	1,530	26,750
Disposals		-	-	(534)	(534)
Effect of change in foreign exchange rates	_	355	33	3	391
Balance as of March 31, 2023	\$_	148,180	143,368	11,992	303,540
Balance as of January 1, 2022	\$	108,020	120,945	5,788	234,753
Depreciation (Note)		14,516	15,969	1,552	32,037
Disposals		(29,377)	(4,341)	(762)	(34,480)
Effect of change in foreign exchange rates	_	2,060	669	12	2,741
Balance as of March 31, 2022	\$_	95,219	133,242	6,590	235,051
				(	(Continued)

Carrying amount:	Land	Buildings and structures	Other equipment	Total
Balance as of January 1, 2023 \$	747,948	341,753	10,028	1,099,729
Balance as of March 31, 2023 \$	735,399	331,013	8,793	1,075,205
Balance as of January 1, 2022 \$	878,849	361,702	15,065	1,255,616
Balance as of March 31, 2022	821,113	408,712	13,632	1,243,457

Note: Including capitalized depreciation expenses transferred to construction in progress, which amounted to \$46 thousand.

#### (k) Investment property

	Land	Buildings and structures	Total
Carrying amount:	_		
Balance as of January 1, 2023	\$ 963,127	85,505	1,048,632
Balance as of March 31, 2023	\$ 963,127	84,176	1,047,303
Balance as of January 1, 2022	\$ 963,127	90,821	1,053,948
Balance as of March 31, 2022	\$ 963,127	89,492	1,052,619
Fair value:	_		
Balance as of January 1, 2023			\$ <u>1,166,818</u>
Balance as of March 31, 2023			\$ 1,172,669
Balance as of March 31, 2022			\$ 1,179,601

There was no significant additions, disposals, or recognition and reversal of impairment losses of investment property for the three months ended March 31, 2023 and 2022. As of March 31, 2023, amortization of investment property was disclosed in Note 12(a). Other information was disclosed in Note 6(m) of the consolidated financial statements for the year ended December 31, 2022.

When measuring the fair value of its investment property, the Group considered the present value of net cash flows to be generated from leasing the property. The expected net cash flows were discounted using the yield to reflect its specified inherit risk on the net cash flows. The inputs to the valuation technique used for measuring fair value were categorized as a Level 2 fair value. As of March 31, 2023, December 31 and March 31, 2022, the yield applied to the net annual rentals to determine fair value of property for which current prices in an active market were unavailable, was as follows:

	March 31,	December 31,	March 31,
Location	2023	2022	2022
Hsinchu	0.25%	0.44%	0.44%

As of March 31, 2023, December 31 and March 31, 2022, the investment properties were not pledged.

# (l) Intangible assets

Carrying amount:	Technica know-hov		Goodwill	Others	Total
Balance as of January 1, 2023	\$35,	792 201,522	324,962	29	562,305
Balance as of March 31, 2023	\$ 34,	355 199,298	323,885	22	557,560
Balance as of January 1, 2022	\$ 44,	318 284,449	312,405	713	641,885
Balance as of March 31, 2022	\$ 41,	895 261,886	316,342	257	620,380

There was no significant additions, disposals, or recognition and reversal of impairment losses of intangible assets for the three months ended March 31, 2023 and 2022. As of March 31, 2023, amortization of intangible assets was disclosed in Note 12(a). Other information was disclosed in Note 6(n) of the consolidated financial statements for the year ended December 31, 2022.

As of March 31, 2023, December 31 and March 31, 2022, the intangible assets were not pledged.

#### (m) Other current assets and other non-current assets

		March 31, 2023	December 31, 2022	March 31, 2022
Tax refund receivables	\$	52,103	41,268	143,744
Other receivables		42,076	56,976	35,090
Prepayments to suppliers		845	142	26,961
Prepaid expenses		104,459	128,128	118,965
Offset against business tax payable		43,699	43,857	210,251
Restricted assets		342,976	269,261	280,186
Refundable deposits		148,445	148,689	153,036
Long-term prepayments to suppliers		55,424	55,424	36,074
Others	_	24,068	24,830	30,335
	\$_	814,095	768,575	1,034,642

# (n) Short-term borrowings

		March 31, 2023	December 31, 2022	March 31, 2022
Secured short-term borrowings (in RMB)	\$_	15,957		11,594
Unsecured short-term borrowings	\$_	_		
Unused bank credit lines for short-term borrowings	\$_	1,650,793	1,205,517	1,558,111
Unused bank credit lines for short-term and long-term borrowings	\$_	2,899,000	3,308,682	4,090,400
Annual interest rate	=	3.70%		3.75%

The collateral for these short-term borrowings were disclosed in Note 8.

# (o) Long-term borrowings

		March 31, 2023	December 31, 2022	March 31, 2022
Secured long-term syndicated borrowings (in USD)	\$	7,983,850	6,984,198	5,718,842
Unsecured long-term borrowings (in TWD)		10,657,247	10,617,247	7,800,747
Less: Current portion	_	(2,473,067)	(1,731,147)	
Total	\$	16,168,030	15,870,298	13,519,589
Unused bank credit lines for long-term borrowings	\$	11,643,250	13,358,568	15,453,368
Annual interest rate	=	0.88%~5.31%	0.75%~4.62%	0.50%~1.10%
Expiry date	20	024/05/17~2029/01/20	2024/05/17~2029/01/20	2024/04/22~2029/01/20

As of March 31, 2023, the remaining balances of the borrowing due were as follows:

Amount
\$ 2,473,067
5,247,680
10,264,850
218,500
437,000
\$ <u>18,641,097</u>

- (i) The unused bank credit lines for short-term and long-term borrowings at the reporting date were disclosed in Note 6(n).
- (ii) The collateral for these long-term borrowings were disclosed in Note 8.
- (iii) In December 2021, the Group entered into a three-year syndicated loan agreement with Far Eastern International Bank and other ten banks. The total credit facility under this loan agreement is US\$300,000 thousand. The loans from the initial withdrawal should be first paid off the outstanding amount of syndicated loan agreement in June 2019.

The related financial covenants and restrictions for the syndicated loans mentioned above were as follows:

- 1) At the end of reporting period, current ratio (current assets / current liabilities): shall not lower than 100%;
- 2) Interest coverage ratio [(profit before tax + depreciation + amortization + interest expense) / interest expense)]: shall not be lower than 100%; and
- 3) Tangible net assets value (equity— intangible assets): shall not be lower than NT\$20,000,000 thousand.

After the guarantor signs the loan agreement, the aforementioned financial ratio and criteria will be reviewed semi-annually, which are based on the year-end consolidated financial statements audited by the Certified Public Accountants (CPAs) that are approved by the leading bank, as well as the semi-annual consolidated financial statements reviewed by the CPAs.

For the six months ended June 30, 2022 and for the year ended December 31, 2022, the Group were in compliance with the above financial covenants and restrictions.

March 21

Dogombon 21

# (p) Bonds payable

The details of bonds payable were as follows:

		2023	2022	2022
Overseas convertible bonds issuance balance	\$	10,952,937	11,092,858	13,992,000
Less: Unamortized discounted bonds payable		(384,145)	(423,303)	(662,710)
Current portion	_	(10,568,792)		
Total	\$_	-	10,669,555	13,329,290

March 21

Proceeds from issuance (less transaction cost amounted to \$89,226 thousand)	\$	13,902,774
Equity components (less transaction cost amortized to equity component of \$4,147		(639,583)
thousand)		
Embedded derivatives instruments—put/ call options	_	(139,920)
Liability components at the issuance date (less transaction cost allocated to liability	y	13,123,271
component of \$85,079 thousand)		
Interest expense at an effective interest rate of 1.28%		358,733
Repurchases of bonds payable	_	(2,913,212)
Liability components at March 31, 2023	\$	10,568,792

The Company resolved to issue the first unsecured overseas convertible bonds, as proposed in the Board of Directors meeting held on November 27, 2020, which had been approved by the Financial Supervisory Commission with approval No.1090377907 on December 25, 2020 and been issued on the Singapore Exchange Securities Trading Limited on January 14, 2021. The Company issued the 5 years unsecured convertible bond, amounting to US\$500,000 thousand without coupon rate, with the maturity dates on January 14, 2026.

Unless previously redeemed, repurchased, and cancelled or converted, regulations and except during the closed period, the bonds may be converted into the Company's common shares pursuant to the applicable laws and regulations and the indenture at any time starting from the next day immediately after three months from the issue date to (1) the 10 day prior to the maturity date or (2) the 5 business day prior to the applicable redemption date on which a bondholder exercises its put right or the applicable date (other than the maturity date) on which the Company exercises its redemption right.

The conversion price was 140% of the closing price of the Company's common shares on the Taipei Exchange on the pricing date, which was NT\$497. The number of common shares to be delivered upon conversion of any bond will be determined with the principal amount of the bonds multiplied by the fixed exchange rate, which is NT\$27.984 to US\$1, which as determined on the pricing date and divided by the conversion price in effect on the date of conversion. After the issuance of the bonds, the conversion price shall be adjusted in accordance with the relevant anti-dilution provisions of the indenture. As of March 31, 2023, the conversion price was adjusted to NT\$464.04 per share.

The above-mentioned convertible bonds included liabilities and equity components. The equity component was accounted under the capital surplus-stock option. The effective interest rate originally recognized for the liability component was 1.28%.

For the three months ended March 31, 2023, the Company has repurchased the first issued unsecured overseas convertible bonds in 2020 at the principle amount of US\$5,000 thousand, and consequently, derecognized the related derivative financial liabilities. The difference between the repurchased amount and the carrying amount was recognized under other gains and losses. There was no such transaction for the three months ended Marth 31, 2022.

## (q) Lease liabilities

The carrying amounts of lease liabilities were as follow:

	March 31, 2023	December 31, 2022	March 31, 2022	
Current	\$ 108,544	103,570	123,352	
Non-current	\$ 904,742	924,832	1,030,059	

For the maturity analysis, please refer to Note 6(aa).

The amounts recognized in profit or loss were as follows:

		the three ths ended	For the three months ended
	Marc	h 31, 2023	March 31, 2022
Interest expenses on lease liabilities	\$	5,982	6,962
Expenses relating to short-term leases	\$	1,094	1,630
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	\$	395	396

The amounts recognized in the statement of cash flows for the Group was as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2023	March 31, 2022
Total cash outflow for leases	\$ 24,358	42,469

# (i) Land, buildings and structures leases

The Group leases land, buildings and structures for its plants, parking lots and staff dormitories. The leases of them typically run for a period of 2 to 50 years.

# (ii) Other leases

The Group leases printer and transportation equipment, with lease terms of 2 to 10 years.

# (iii) Others

Parts of the leases of transportation equipment, machinery and equipment, office and staff dormitories are with contract terms of less than one year. These leases are short-term. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases. Also, some leases contain cancellation options exercisable by the Group. In which lease is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

# (r) Operating lease

There were no significant changes in operating lease for the three months ended March 31, 2023 and 2022. Please refer to Note 6(t) of the consolidated financial statements for the year ended December 31, 2022 for other related information.

# (s) Employee benefits

#### (i) Defined benefit plans

At the end of the prior fiscal year, there was no material volatility of the market, no material reimbursement and settlement or other material one-time events. As a result, pension cost in the consolidated interim financial statements was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate as of December 31, 2022 and 2021.

The Group's expenses recognized in profit or loss were as follows:

		For the three months ended March 31, 2022
Operating costs	\$ -	-
Operating expenses	591	450
	<u>\$</u> 591	450

# (ii) Defined contribution plans

The Group's expenses under the pension plan cost to the Bureau of Labor Insurance were as follows:

	For the three months ended	months ended	
	March 31, 2023	March 31, 2022	
Operating costs	\$ 23,926	26,605	
Operating expenses	7,841	7,169	
	\$31,767	33,774	

(iii) The Group's mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. Other than the monthly contributions, the Group has no further obligations. For the three months ended March 31, 2023 and 2022, the Group recognized the pension costs in accordance with the pension regulations and amounted to \$4,720 thousand and \$4,683 thousand, respectively.

# (t) Income tax

(i) The amount of income tax expense (benifit) was as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2023	March 31, 2022
Income tax expense (benifit)	\$ (76,998)	204,704

(ii) There was no income tax expense recognized in other comprehensive income for the three months ended March 31, 2023 and 2022.

#### (iii) Assessment

The Company's corporate income tax returns for all the years through 2020 were assessed by the tax authorities.

# (u) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the three months ended March 31, 2023 and 2022. For the related information, please refer to Note 6(w) of the consolidated financial statements for the year ended December 31, 2022.

# (i) Capital surplus

Balance of capital surplus at the reporting date were as follows:

	March 31, 2023		December 31, 2022	March 31, 2022	
Additional paid-in capital	\$	9,234,813	9,234,813	9,190,855	
Equity component of convertible bonds		639,583	639,583	639,583	
Changes in ownership interests in subsidiaries		85,565	85,565	85,565	
Changes in equity of associates accounted for using equity method		1,849	882	1,419	
Employee stock options		3,245	3,245	3,245	
Restricted shares of stock issued for employees	s _			50,156	
	\$_	9,965,055	9,964,088	9,970,823	

# (ii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the balance of annual income or earnings after deducting accumulated deficit, if any, must be set aside as a legal reserve and a special capital reserve is likewise appropriated or the annual income or earnings are retained in accordance with the relevant laws or regulations or as requested by the authorities, but the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. Otherwise, the Company shall set aside at least 50% for shareholder, the distribution of remaining balance of the earnings should be further proposed by the Board of Directors and resolved by the shareholders' meeting. And the cash dividends should not lower than 10% of the total stockholders' dividends.

It is authorized the distributable dividends and bonuses or legal capital reserve and capital reserve in whole or in part may be paid in cash after a resolution has been adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting.

As the Company is a technology and capital-intensive enterprise and is in its growth phase, it has adopted a more prudent approach in appropriating its remaining earnings as its dividend policy in order to sustain its long-term capital needs and thereby maintain continuous development and steady growth.

The appropriations of earning for 2022 and 2021 had been approved in the meeting of Board of Directors held on March 9, 2023 and March 18, 2022, respectively. The appropriations and dividends were as follows:

 Cash dividends
 2022
 2021

 \$ 1,059,851
 3,391,811

The related information mentioned above can be found on websites such as the Market Observation Post System.

# (iii) Other equity interests, net of tax

	Exchange gains (losses) of financial asset differences on at fair value translation of through other foreign financial statements income		
Balance as of January 1, 2023	\$	61,004	712,629
Foreign currency differences (net of tax):			
The Group		32,085	-
Associates		33,776	-
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax):			
The Group			354,727
Balance as of March 31, 2023	\$	126,865	1,067,356

Unroalized

	Unrealized gains (losses) on				
		Exchange ferences on inslation of ign financial tatements	financial assets at fair value through other comprehensive income	Other unearned compensation for restricted shares of employees	
Balance as of January 1, 2022	\$	(269,409)	1,044,071	(6,597)	
Foreign currency differences (net of tax):					
The Group		319,011	-	-	
Associates		69,744	-	-	
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax):					
The Group		-	(84,825)	-	
Associates		-	579	-	
Compensation cost arising from restricted shares of employees	_			4,398	
Balance as of March 31, 2022	\$	119,346	959,825	(2,199)	

# (v) Share-based payment

Except for the following disclosure, there were no significant changes for share-based payment for the three months ended March 31, 2023 and 2022. For the related information, please refer to Note 6(x) of the consolidated financial statements for the year ended December 31, 2022.

(i) The Company issued restricted shares of stock for employees

For the three months ended March 31, 2023 and 2022, the Company recognized the compensation cost of \$0 thousand and \$4,398 thousand for the aforementioned RSA, respectively.

(ii) The employee stock option (ESOPs) of subsidiary (PBL)

For the three months ended March 31, 2023 and 2022, PBL recognized the compensation cost of \$5,514 thousand and \$0 thousand for the aforementioned ESOPs, respectively.

# (w) Earnings per share ("EPS")

	mo	r the three nths ended rch 31, 2023	For the three months ended March 31, 2022
Basic earnings per share:			
Profit (loss) belonging to common shareholders	\$	(401,811)	882,221
Weighted-average number of outstanding shares of common stock (in thousands shares)		423,940	423,714
Basic earnings per share (in dollars)	\$	(0.95)	2.08

	m	or the three onths ended orch 31, 2023	For the three months ended March 31, 2022
Diluted earnings per share:			
Profit (loss) belonging to common shareholders	\$	(401,811)	882,221
Interest expense and other gains and losses on convertible bonds, net of ta	x	(107,001)	
Profit (loss) belonging to common shareholders (diluted)	<b>\$</b>	(508,812)	882,221
Weighted-average number of outstanding shares of common stock (in thousands shares)		423,940	423,714
Effect of potentially dilutive common stock			
Employee remuneration (in thousands shares)		-	1,563
Restricted employee shares (in thousands shares)		-	255
Effect of conversion of convertible bonds (in thousands shares)		23,905	
Weighted-average number of common stock (diluted) (in thousands shares	s)	447,845	425,532
Diluted earnings per share (in dollars)	\$	(1.14)	2.07

For the three months ended March 31, 2023, the employee compensation had anti-diluted effects and hence the employee compensation was not included in the calculation of effect on potentially diluted common stock. Furthermore, for the three months ended March 31, 2022, the convertible bonds had anti-diluted effects if the bonds were converted, and hence the convertible bonds were not included in the calculation of effect on potentially diluted common stock.

## (x) Revenue from contracts with customers

## (i) Disaggregation of revenue

		For the three months ended March 31, 2023							
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total				
Primary geographical markets:									
Asia	\$	1,592,954	109,647	184,939	1,887,540				
Americas		643,063	-	10,543	653,606				
Taiwan		120,892	791	23,431	145,114				
Europe	_	159,996		13,302	173,298				
	\$_	2,516,905	110,438	232,215	2,859,558				
Main product/ services lines:									
Foundry	\$	2,516,129	-	-	2,516,129				
Others	_	776	110,438	232,215	343,429				
	\$_	2,516,905	110,438	232,215	2,859,558				

For the three months ended March 31, 2022

	For the three months ended waren 31, 2022						
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total		
Primary geographical markets	:						
Asia	\$	3,514,274	47,573	5,422	3,567,269		
Americas		1,503,112	-	8,746	1,511,858		
Taiwan		252,090	16	37,039	289,145		
Europe	_	229,003		(282)	228,721		
	\$_	5,498,479	47,589	50,925	5,596,993		
Main product/ services lines:							
Foundry	\$	5,498,479	-	-	5,498,479		
Others	_		47,589	50,925	98,514		
	\$_	5,498,479	47,589	50,925	5,596,993		

Note: Segment-others were mainly general investment businesses, and their net investment profits and losses were recognized as operating revenue.

### (ii) Balance of contracts

	M	arch 31, 2023	December 31, 2022	March 31, 2022	
Notes receivable	\$	839	1,310	965	
Accounts receivable		778,610	916,315	2,019,517	
Less: loss allowance		(1,928)	(985)	(798)	
	\$	777,521	916,640	2,019,684	
Contract liabilities	\$	309,002	235,309	249,011	

For details of notes and accounts receivable and allowance for impairment, please refer to Note 6(c).

The major change in the balance of contract liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received. The amount of revenue recognized for the three months ended March 31, 2023 and 2022 that was included in the contract liabilities balance at the beginning of the period was \$157,375 thousand and \$269,854 thousand, respectively.

#### (y) Employees' and directors' remuneration

According to the Company's Article of Incorporation, if there is any net profit after closing of a fiscal year, it shall be allocated according to the following principles:

- (i) Employees' remuneration: not less than 5% but no more than 10% and shall be determined and pursuant to Employee Bonus Procedure of the Company. In addition, employee's profit-sharing remuneration shall be distributed in the form of shares or cash. Stock-type employee remuneration may be distributed to qualified employees of affiliates of the Company.
- (ii) Directors's remuneration: no more than 3%.

However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss. The distribution of employees' remuneration and directors's remuneration shall follow the special resolution by Board of Directors, and report it to the shareholders' meeting.

The Company estimated its employees' and directors' remuneration as follows:

	months ended March 31, 2023	months ended March 31, 2022
Employees' remuneration	\$ -	77,000
Directors' remuneration		22,400
	<u> </u>	99,400

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration and accumulated losses, and then multiplied by the rule of Company's Article of Incorporation. The above remuneration was included in the operating costs and operating expenses of for the three months ended March 31, 2023 and 2022. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

For the years ended December 31, 2022 and 2021, the Company accrued and recognized its employees' remuneration amounting to \$149,000 thousand and \$447,000 thousand, and directors' remuneration amounting to \$38,000 thousand and \$129,000 thousand, respectively. There were no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements. The related information mentioned above can be found on websites such as the Market Observation Post System.

# (z) Non-operating income and expenses

/*>	T .	
(i)	) Interest	ıncome

	Interest income from bank deposits Other interest income Interest income	moi	r the three nths ended ch 31, 2023 53,911 33 53,944	For the three months ended March 31, 2022 5,397 17 5,414
(ii)	Other income			
		mon	the three ths ended	For the three months ended March 31, 2022
	Dividend income	\$	6,750	72,311
	Rent income		10,512	9,263
	Other income	\$	17,262	81,574
(iii)	Other gains and losses			
		mon	the three ths ended	For the three months ended March 31, 2022
	Losses on disposals of property, plant and equipment	\$	(22,826)	
	Foreign exchange gains (losses)		(6,447)	338,919
	Gains (losses) on financial assets or liabilities at fair value through profit or loss		155,785	(279,040)
	Gains on repurchases of bonds payable		15,316	-
	Losses on lease modification		-	(21,721)
	Others		(19,383)	(31,414)
	Other gains and losses	\$	122,445	6,602

### (iv) Finance costs

	mo	r the three nths ended rch 31, 2023	For the three months ended March 31, 2022
Interest expenses			
Bank borrowings	\$	149,213	45,772
Bonds payable		34,178	42,651
Lease liabilities		5,982	7,008
Less: capitalized interest		(50,954)	(14,966)
Subtotal of interest expenses		138,419	80,465
Other finance costs		161	36
Finance costs	\$	138,580	80,501

#### (aa) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information, please refer to Note 6(ac) of the consolidated financial statements for the year ended December 31, 2022.

#### (i) Credit risk

#### 1) Receivables and debt securities

For information on credit risk regarding notes and accounts receivable, please refer to Note 6(c).

Other financial assets measured at amortized cost include other receivables. For related information of investment and impairment, please refer to Note 6(d).

All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited 12 months expected losses.

## (ii) Liquidity risk

The following were the contractual maturities of financial liabilities:

	Carrying amount	Contractual cash flows	Within 1 year	1-2 years	2-5 years	Over 5 years
As of March 31, 2023						
Non-derivative financial liabilities						
Secured bank loans	\$ 7,999,807	8,946,710	430,832	414,397	8,101,481	-
Unsecured bank loans	10,657,247	10,904,091	2,601,907	5,330,022	2,751,925	220,237
Bonds payable	10,568,792	10,628,430	10,628,430	-	-	-
Accounts payable	724,935	724,935	724,935	-	-	-
Other payables	2,900,174	2,900,174	2,900,174	-	-	-
Guarantee deposits received	119,347	119,347	612	8,735	-	110,000
Lease liabilities	1,013,286	1,212,615	119,520	105,755	268,842	718,498
	\$ 33,983,588	35,436,302	17,406,410	5,858,909	11,122,248	1,048,735
As of December 31, 2022						
Non-derivative financial liabilities						
Secured bank loans	\$ 6,984,198	8,183,035	326,332	326,331	7,530,372	-
Unsecured bank loans	10,617,247	10,874,528	1,855,307	3,705,258	5,030,702	283,261
Bonds payable	10,669,555	10,764,204	-	10,764,204	-	-
Notes and accounts payable	1,016,716	1,016,716	1,016,716	-	-	-
Other payables	2,362,432	2,362,432	2,362,432	-	-	-
Guarantee deposits received	119,299	119,299	610	8,689	-	110,000
Lease liabilities	1,028,402	1,233,131	114,743	107,306	284,170	726,912
	\$ <u>32,797,849</u>	34,553,345	5,676,140	14,911,788	12,845,244	1,120,173
As of March 31, 2022						
Non-derivative financial liabilities						
Secured bank loans	\$ 5,730,436	5,891,895	58,933	47,016	5,785,946	-
Unsecured bank loans	7,800,747	7,946,195	59,892	2,524,734	4,983,194	378,375
Bonds payable	13,329,290	13,577,452	-	13,577,452	-	-
Accounts payable	1,530,971	1,530,971	1,530,971	-	-	-
Other payables	7,327,062	7,327,062	7,327,062	-	-	-
Guarantee deposits received	119,377	119,377	161	119,216	-	-
Lease liabilities	1,153,411	1,409,806	135,283	122,477	301,369	850,677
	\$ 36,991,294	37,802,758	9,112,302	16,390,895	11,070,509	1,229,052

The Group did not expect that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

## (iii) Currency risk

## 1) Exposure to currency risk

The Group's significant exposure to foreign currency risk were as follows:

	March 31, 2023			December 31, 2022			March 31, 2022			
		Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$
Financial assets										
Monetary items										
USD	\$	291,188	30.45	8,866,668	279,147	30.71	8,572,598	368,383	28.63	10,546,806
EUR		81	33.15	2,699	607	32.72	19,877	2,701	31.92	86,219
ЈРҮ		377,197	0.2288	86,303	727,741	0.2324	169,127	1,646,794	0.2353	387,491
GBP		11	37.67	416	11	37.09	409	11	37.62	414
HKD		58	3.879	226	59	3.938	232	59	3.656	216
RMB		66	4.43	290	323	4.41	1,423	1,827	4.51	8,242
SGD		1	22.91	20	1	22.88	20	1	21.16	18
			\$	8,956,622		;	§ 8,763,686		;	§ 11,029,406
Non-monetary items										
USD	\$	18,186	30.45	553,774	18,332	30.71	562,980	26,886	28.63	769,741
RMB		254,679	4.43	1,126,806	221,729	4.41	975,781	236,101	4.51	1,062,508
			\$	1,680,580		:	\$ 1,538,761		:	1,832,249
Financial liabilities										
Monetary items										
USD	\$	236,627	30.45	7,205,307	206,821	30.71	6,351,478	216,790	28.63	6,206,686
EUR		139	33.15	4,610	226	32.72	7,395	2,565	31.92	81,888
JPY		342,224	0.2288	78,301	366,445	0.2324	85,162	805,718	0.2353	189,585
			\$	7,288,218		:	§ 6,444,035		:	6,478,159

#### 2) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, notes and accounts receivable, other receivables, financial assets at fair value through profit or loss, notes and accounts payable, other payables, long-term borrowings, etc. that are denominated in foreign currency. A strengthening (weakening) 5% of appreciation (depreciation) of the TWD against the USD, EUR, GBP, JPY, HKD, RMB, SGD, etc. for the three months ended March 31, 2023 and 2022 would have increased (decreased) the net profit (loss) after tax by \$88,887 thousand and \$212,844 thousand, respectively. The analysis assumes that all other variables remain constant.

### 3) Exchange gains or losses

Since the Group has many kinds of functional currency, the information on foreign exchange gains (losses) on monetary items is disclosed by total amount. For three months ended March 31, 2023 and 2022, foreign exchange gains (losses) (including realized and unrealized portions) amounted to \$(6,447) thousand and \$338,919 thousand, respectively.

#### (iv) Interest rate risk

Please refer to the attached note for the liquidity risk and the Group's interest rate exposure to its financial liabilities.

The following sensitivity analysis is based on the risk exposure to interest rates on the nonderivatives financial instruments on the reporting date. For variable rate instruments, the sensitivity analysis assumes the variable rate liabilities are outstanding for the whole year on the reporting date.

If the interest rate increases (decreases) by 0.5%, the Group's net profit (loss) after tax would have increased (decreased) by \$18,668 thousand and \$14,561 thousand for the three months ended March 31, 2023 and 2022, respectively, all other variable factors that remain constant. This is mainly due to the Group's borrowing in floating rates.

#### (v) Fair value

#### 1) Financial instrument classifications and fair values

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities disclosure of fair value information is not required.

	March 31, 2023 Fair value							
	Ca	rrying value	Level 1	Level 2	Level 3	Total		
Financial assets at fair value through profit or loss								
Publicly traded stocks	\$	482,729	482,729	-	-	482,729		
Funds and investment		111,617	111,617	-	-	111,617		
Private fund	_	1,400,193			1,400,193	1,400,193		
Subtotal	\$	1,994,539	594,346		1,400,193	1,994,539		
Financial assets at fair value through other comprehensive inc	ome							
Stocks listed on domestic and foreign markets	\$	1,547,641	1,547,641	-	-	1,547,641		
Non-public stocks		648,466			648,466	648,466		
Subtotal	\$	2,196,107	1,547,641		648,466	2,196,107		
Financial assets measured at amortized cost								
Cash and cash equivalents (Note)	\$	10,406,167	-	-	-	-		
Notes and accounts receivable (Note)		777,521	-	-	-	-		
Other receivables (Note)		42,076	-	-	-	-		
Other non-current assets (Note)		491,421			<u> </u>	-		
Subtotal	\$	11,717,185			<u> </u>	-		
Financial liabilities at fair value through profit or loss								
Derivative financial liabilities	\$	306,682	<u>-</u>	306,682		306,682		

	March 31, 2023					
	Ca	rrying value	Level 1	Fair va	Level 3	Total
Financial liabilities measured at amortized cost						
Bank loans (Note)	\$	18,657,054	-	-	-	-
Bonds payable (Note)		10,568,792	-	-	-	-
Accounts payable (Note)		724,935	-	-	-	-
Other payables (Note)		2,900,174	-	-	-	-
Guarantee deposits received (Note)		119,347	-	-	-	-
Lease liabilities (Note)		1,013,286	<u> </u>			-
Subtotal	<u></u>	33,983,588				
			Dec	ember 31, 2022		
	Co	rrying value	Level 1	Fair va	Level 3	Total
Financial assets at fair value through profit or loss		rrying value	Level I	Level 2	Level 5	Total
Publicly traded stocks	\$	301,109	301,109	-	-	301,109
Funds and investment		111,296	111,296	-	-	111,296
Private fund		1,369,943	-	-	1,369,943	1,369,943
Subtotal	\$	1,782,348	412,405	-	1,369,943	1,782,348
Financial assets at fair value through other comprehensive inc	come					
Stocks listed on domestic and foreign markets	\$	1,361,612	1,361,612	-	-	1,361,612
Non-public stocks		480,320		<u> </u>	480,320	480,320
Subtotal	\$	1,841,932	1,361,612	<u> </u>	480,320	1,841,932
Financial assets measured at amortized cost						
Cash and cash equivalents (Note)	\$	10,379,712	-	-	-	-
Notes and accounts receivable (Note)		916,640	-	-	-	-
Other receivables (Note)		56,976	-	-	-	-
Other non-current assets (Note)		417,950	<u> </u>	<u> </u>		-
Subtotal	<u></u>	11,771,278				
Financial liabilities at fair value through profit or loss		<u> </u>				
Derivative financial liabilities	\$	449,261		449,261		449,261
Financial liabilities measured at amortized cost		<u> </u>				
Bank loans (Note)	\$	17,601,445	-	-	-	-
Bonds payable (Note)		10,669,555	-	-	-	-
Notes and accounts payable (Note)		1,016,716	-	-	-	-
Other payables (Note)		2,362,432	-	-	-	-
Guarantee deposits received (Note)		119,299	-	-	-	-
Lease liabilities (Note)		1,028,402				-
Subtotal	<u></u>	32,797,849		<u> </u>	<u> </u>	<u> </u>

	March 31, 2022					
				Fair va		
Financial assets at fair value through profit or loss	_Ca	rrying value	Level 1	Level 2	Level 3	Total
Stocks listed on domestic markets	\$	14,197	14,197	-	-	14,197
Non-public stocks		398,433	-	-	398,433	398,433
Funds and investment		42,360	42,360	-	-	42,360
Private fund		1,542,726	-	-	1,542,726	1,542,726
Subtotal	\$	1,997,716	56,557	-	1,941,159	1,997,716
Financial assets at fair value through other comprehensive inc	come					
Stocks listed on domestic and foreign markets	\$	1,445,713	1,445,713	-	-	1,445,713
Non-public stocks		651,391		-	651,391	651,391
Subtotal	\$	2,097,104	1,445,713	-	651,391	2,097,104
Financial assets measured at amortized cost	_					
Cash and cash equivalents (Note)	\$	14,207,296	-	-	-	-
Notes and accounts receivable (Note)		2,019,684	-	-	-	-
Other receivables (Note)		35,090	-	-	-	-
Other non-current assets (Note)		433,222			<u> </u>	-
Subtotal	\$	16,695,292				-
Financial liabilities at fair value through profit or loss						
Derivative financial liabilities	\$	526,099		526,099	<u> </u>	526,099
Financial liabilities measured at amortized cost						
Bank loans (Note)	\$	13,531,183	-	-	-	-
Bonds payable (Note)		13,329,290	-	-	-	-
Accounts payable (Note)		1,530,971	-	-	-	-
Other payables (Note)		7,327,062	-	-	-	-
Guarantee deposits received (Note)		119,377	-	-	-	-
Lease liabilities (Note)	_	1,153,411				-
Subtotal	\$	36,991,294				-

Note: The information on fair value is not disclosed since the carrying amount is a reasonable approximation of fair value.

## 2) Valuation techniques of financial instrument not valued at fair value

The valuation techniques of the Group's financial instruments not valued at fair value by using the methods and assumptions are as follows:

• Financial assets measured at amortized cost and financial liabilities measured at amortized cost.

If recent transaction prices or market maker quotes are available, the fair value is based on such information. If there is no quoted market price available, the fair value is determined by using valuation techniques and calculated as the present value of the estimated cash flows.

- 3) Valuation techniques of financial instruments valued at fair value
  - a) Non-derivative instruments

The fair value of financial assets and liabilities traded in an active market is based on the quoted market prices. The quotation, which is published by the main exchange center or that which was deemed to be a public bond by the Treasury Bureau of Central Bank, is included in the fair value of the listed securities instruments and the debt instruments in active markets with open bid.

A financial instrument is regarded as the quoted price in an active market if the quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency; and if those prices represent the actual and regularly occurring market transactions on an arm's length basis. Otherwise, the market is deemed to be inactive. Normally, a market is considered to be inactive when:

- The bid-ask spread is increasing; or
- The bid-ask spread varies significantly; or
- There has been a significant decline in trading volume.

When the financial instrument of the Group is traded in an active market, its fair value is illustrated by the category and nature as follows:

- Financial assets and liabilities with standard terms and conditions and traded in an active market, for example, investment in stock of listed companies: the fair value is based on the market quoted price.
- Close-end funds with standard terms and conditions, such as money market funds; investors can require the investment trust company to redeem the fund at any time. The fair value is based on the net value of the fund.

Except for the above-mentioned financial instruments traded in an active market, the fair value is based on the valuation techniques or the quotation from the counter-party. The fair value refers to the current fair value of the other financial instruments with similar conditions and characteristics, using a discounted cash flow analysis or other valuation techniques, such as calculations of using models (for example, applicable yield curve from Taipei Exchange, or average quoted price on interest rate of commercial paper from Reuters), based on the information acquired from the market at the balance sheet date.

When the financial instrument of the Group is not traded in an active market, its fair value is determined as follows:

- The fair value is determined based on the ratio of the quoted market price of the comparative listed company and its book value per share and its sales revenue per share. Also, the fair value is discounted for its lack of liquidity in the market.
- The fair value is determined by using the asset-based approach, whose assumptions are based on the market approach, income approach, cost approach or other valuation methods according to the nature of the assets or liabilities of the subject companies.

#### b) Derivative instruments

The fair value is determined by using the models that are acceptable to the market participants, for example, discounted cash flow analyses or option pricing models. Forward exchange contracts are measured using quoted forward exchange rates. The fair value of structured interest derivative financial instruments is determined by using the proper option pricing models, such as Black-Scholes model, or other valuation technique, such as Monte Carlo simulation.

### 4) Level transfers of financial instruments

For the three months ended March 31, 2023 and 2022, there was no transfer of financial instrument.

#### 5) Movement of level 3

	<u>_</u> F	Fair value throu Unquoted equity instruments	gh profit or loss  Private fund	Fair value through other comprehensive income Unquoted equity instruments
Balance as of January 1, 2023	\$	-	1,369,943	480,320
Total gains or losses:				
Recognized in profit and loss		-	16,968	-
Recognized in other comprehensive income		-	-	168,405
Purchased		-	15,490	-
Capital reduction		-	(2,208)	-
Effect of changes in foreign exchange rates	_			(259)
Balance as of March 31, 2023	\$_		1,400,193	648,466
	_			

Fair value

## WIN Semiconductors Corp. and Subsidiaries Notes to the Consolidated Financial Statements

	<u> </u>	Fair value throug Unquoted equity	through other comprehensive income Unquoted equity	
		instruments	Private fund	instruments
Balance as of January 1, 2022	\$	380,417	1,442,016	680,342
Total gains or losses:				
Recognized in profit and loss		4,927	60,937	-
Recognized in other comprehensive income		-	-	(23,234)
Purchased		-	45,162	-
Capital reduction		-	(5,389)	(6,667)
Effect of changes in foreign exchange rates	_	13,089		950
Balance as of March 31, 2022	\$_	398,433	1,542,726	651,391

The preceding gains and losses were recognized as "other gains and losses" and "unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income". As of March 31, 2023 and 2022, the related information of the assets which were still held by the Group were as follows:

	mon	ths ended	months ended March 31, 2022	
Total gains or losses			_	
Profit or loss (recognized as other gains and losses)	\$	16,968	65,864	
Other comprehensive income (recognized as unrealized				
gains (losses) from investments in equity instruments				
measured at fair value through other comprehensive				
income)		168,405	(23,234)	

6) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include "financial assets at fair value through profit or loss — equity investment", "financial assets at fair value through profit or loss — private funds" and "financial assets at fair value through other comprehensive income — equity investments."

Most of the fair value measurements categorized within Level 3 use the single and significant unobservable input. Equity investments without an active market contains multiple significant unobservable inputs. The significant unobservable inputs of the equity investments are independent from each other, as a result, there is no relevance between them.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationships between significant unobservable inputs and fair value measurement
	Comparable listed companies approach	• Price-book ratio (as of March 31, 2023, December 31 and March 31, 2022 were 1.68~4.81, 1.58~4.05 and 1.71~4.77,	The higher the price- book ratio, the higher the fair value
	•	respectively)  • Market liquidity discount rate (as of March 31, 2023, December 31 and March 31, 2022 were all 20%)	The higher the market liquidity discount rate, the lower the fair value
	Net asset value method	Net asset value	• The higher the net assets value, the higher the fair value
Financial assets at fair value through profit or loss – equity investments without an active market	Comparable listed companies approach	<ul> <li>Price-to-sale ratio (as of March 31, 2022 was 6.30)</li> <li>Market liquidity discount rate (as of</li> </ul>	• The higher the price-to sales ratio, the higher the fair value
		March 31, 2022 was 20%)	• The higher the market liquidity discount rate, the lower the fair value
Financial assets at fair value through profit or loss – private fund	Net asset value method	Net asset value	The higher the net assets value, the higher the fair value

7) Sensitivity analysis of reasonably possible alternative assumptions for fair value measurements in Level 3 of the fair value hierarchy

The fair value measurements of the Group's financial instruments are reasonable. However, changes in the use of valuation models or valuation variables may affect the estimations. For fair value measurements in Level 3, a fluctuation in the valuation variable by 5% would have the following effect:

			_	Effects of ch	U	Effects of changes in fair value on other comprehensive income	
March 31, 2023	Inputs	Increase or decrease		Favorable	<u>Unfavorable</u>	Favorable	<u>Unfavorable</u>
Financial assets at fair value through profit or loss							
Private fund	Net asset value	5%	\$	70,010	(70,010)	-	-
Financial assets at fair value through other comprehensive income							
Equity investments without an active market	Price-book ratio	5%		-	-	23,585	(23,585)
n	Market liquidity discount rate	5%		-	-	23,585	(23,585)
//	Net asset value	5%		-	-	8,838	(8,838)

			Effects of changes in fai value on profit or loss			Effects of changes in fair value on other comprehensive income	
	Inputs	Increase or decrease		Favorable	<u>Unfavorable</u>	Favorable	<u>Unfavorable</u>
December 31, 2022							
Financial assets at fair value through profit or loss							
Private fund	Net asset value	5%	\$	68,497	(68,497)	-	-
Financial assets at fair value through other comprehensive income							
Equity investments without an active market	Price-book ratio	5%		-	-	6,611	(6,611)
"	Market liquidity discount rate	5%		-	-	6,611	(6,611)
//	Net asset value	5%		-	-	17,406	(17,406)
March 31, 2022							
Financial assets at fair value through profit or loss							
Equity investments without an active market	Price-to-sales ratio	5%	\$	19,922	(19,922)	-	-
"	Market liquidity discount rate	5%		19,922	(19,922)	-	-
Private fund	Net asset value	5%		77,136	(77,136)	-	-
Financial assets at fair value through other comprehensive income							
Equity investments without an active market	Price-book ratio	5%		-	-	12,517	(12,517)
"	Market liquidity discount rate	5%		-	-	12,517	(12,517)
"	Net asset value	5%		-	-	20,052	(20,052)

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the inter-relationships with another input.

## (ab) Management of financial risk

There was no significant change in the Group's objective and policies for the management of financial risk of the consolidated financial statements for the three months ended March 31, 2023 which compared with the consolidated financial statements Note 6(ad) for the year ended December 31, 2022.

## (ac) Capital management

TheGroup's objective, policies and process of capital management of the consolidated financial statements for the three months ended March 31, 2023 was the same as the consolidated financial statements for the year ended December 31, 2022. For the related information, please refer to Note 6(ae) of the consolidated financial statements for the year ended December 31, 2022.

As of March 31, 2023, December 31 and March 31, 2022, the Group's return on common equity was (4.90)%, 5.28% and 10.43%, respectively. The Group's debt ratio at the reporting date was as follows:

	March 31, 2023	December 31, 2022	March 31, 2022
Debt ratio	50.68 %	49.10 %	52.89 %

Cash flows

### (ad) Financing activity

Reconciliations of liabilities arising from financing activities were as follows:

	Janı	ıary 1, 2023	Proceeds from long- term debt	Repayments of long-term debt and lease liabilities	Others	Interest expense	Others	Amortization of arranger fee of syndicated loan	March 31, 2023
Short-term borrowings	\$	-	15,957	-	-	-	-	-	15,957
Long-term borrowings		17,601,445	1,679,764	(590,000)	-	-	(59,118)	9,006	18,641,097
Bonds payable		10,669,555	-	-	-	34,178	(134,941)	-	10,568,792
Guarantee deposit received		119,299	-	-	48	-	-	-	119,347
Lease liabilities		1,028,402		(19,259)	(3,610)	5,982	1,771		1,013,286
Total liabilities from financing activity	s	29,418,701	1,695,721	(609,259)	(3,562)	40,160	(192,288)	9,006	30,358,479
				Cash flows		No	n-cash change	es	
	Janu	uary 1, 2022	Proceeds from long- term debt and bonds payable	Repayments of long-term debt and lease liabilities	Others	Interest expense	Others	Amortization of arranger fee of syndicated loan	March 31, 2022
Short-term borrowings	\$	-	11,594	-	-	-	-	-	11,594
Long-term borrowings		15,992,820	1,453,200	(4,123,113)	-	-	189,683	6,999	13,519,589
Bonds payable		13,286,639	-	-	-	42,651	-	-	13,329,290
Guarantee deposit received		130,398	-	-	(11,021)	-	-	-	119,377
Lease liabilities (Note)		1,157,209		(27,389)	(13,054)	7,008	29,637		1,153,411
Total liabilities from financing activity	\$	30,567,066	1,464,794	(4,150,502)	(24,075)	49,659	219,320	6,999	28,133,261

Note: Interest expense includes capitalized interest expense transferred to construction in progress, which amounted to \$46 thousand.

## (7) Related-party transactions:

(a) Names and relationship with related parties

The followings are entities that have had transactions with related party during the periods covered in the consolidated financial statements:

Name of related party	Relationship with the Group
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev.	Associates
Jiangsu CM/Chainwin)	
ITEQ Corporation (abbrev. ITEQ)	Associates
Taoyuan i-Fare Charity Foundation	Other related parties

- (b) Significant transactions with related parties
  - (i) Operating expenses

The amounts of operating expenses by the Group from related parties were as follows:

		For the three months ended
		March 31, 2022
Other related parties	\$3,161	

(ii) Guarantee

As of March 31, 2023, December 31, and March 31, 2022, Chainwin Cayman had provided a guarantee for loans amounting to US\$7,350 thousand (\$223,808 thousand, \$225,719 thousand and \$210,431 thousand, respectively) to its associate, Jiangsu CM/Chainwin.

(iii) Leases

The Group leased the office and factories to its associate, ITEQ, and the rent income received monthly is based on the nearby office and factories rental rates. The amount of rent income is \$7,717 thousand and \$7,376 thousand for the three months ended March 31, 2023 and 2022. The preceding rent payment has been received. The guarantee deposits received amounted to \$110,000 thousand as of March 31, 2023, December 31, and March 31, 2022.

(c) Transactions with key management personnel

Key management personnel compensation was comprised as below:

	For the three months ended		For the three months ended	
	Ma	rch 31, 2023	March 31, 2022	
Short-term employee benefits	\$	41,960	108,390	
Post-employment benefits		314	315	
	\$	42,274	108,705	

## (8) Pledged assets:

The carrying amounts of pledged assets were as follows:

Pledged assets	Pledged to secure		March 31, 2023	December 31, 2022	March 31, 2022
Other non-current assets	Land, plant, and dormitory lease guarantee	\$	23,556	36,301	35,438
Other non-current assets	Bank borrowings		170,275	120,658	155,643
Other non-current assets	Gas deposits		4,700	4,700	4,700
Other non-current assets	Customs guarantee with interest		20,736	20,736	20,579
Other non-current assets	Guarantee deposits of letters of credit		-	-	31,012
Other non-current assets	Seized funds and court security deposits		123,709	86,866	32,814
Property, plant and	Bank borrowings				
equipment		_	2,132,518	2,154,811	2,221,763
Total		\$_	2,475,494	2,424,072	2,501,949

## (9) Commitments and contingencies:

(a) Contingencies: None.

#### (b) Commitment:

(i) The unrecognized commitment of acquisition of plant expansion and machinery equipment was as follows:

		March 31, 2023	December 31, 2022	March 31, 2022
The unrecognized amount	\$_	5,479,883	5,891,406	9,763,107

(ii) The unused letters of credit was as follows:

	March 31,	December 31,	March 31,
	2023	2022	2022
The unused letters of credit	\$	5,967	40,360

## (10) Losses due to major disasters: None.

## (11) Subsequent events:

The Company has repurchased the first issued unsecured overseas convertible bonds in 2020 at the principle amount of US\$112,000 thousand after the end of reporting period.

### (12) Other:

(a) The followings were the summary statement of employee benefits, depreciation and amortization expenses by function:

	For the three	e months ended 2023	March 31,	For the three	e months ended 2022	March 31,
	Classified as operating costs	Classified as operating expenses	Total	Classified as operating costs	Classified as operating expenses	Total
Employee benefits						
Salaries	535,583	235,112	770,695	709,459	286,667	996,126
Labor and health insurance	60,843	20,814	81,657	75,609	22,457	98,066
Pension	25,749	11,329	37,078	28,042	10,865	38,907
Director remuneration	-	12	12	-	22,452	22,452
Others	25,438	6,005	31,443	30,583	11,664	42,247
Depreciation	862,993	214,192	1,077,185	939,151	118,625	1,057,776
Amortization	7,819	21,625	29,444	8,388	27,940	36,328

### (b) Seasonality of operations:

The Group's operations were not affected by seasonality or cyclicality factors.

#### (13) Other disclosures:

(a) Information on significant transactions:

The following were the information on significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the Group for the three months ended March 31, 2023:

- (i) Loans to other parties: Please refer to schedule A.
- (ii) Guarantees and endorsements for other parties: Please refer to schedule B.
- (iii) Securities held as of March 31, 2023 (excluding investment in subsidiaries, associates and joint ventures): Please refer to schedule C.
- (iv) Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule D.
- (v) Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule E.

- (vi) Information on disposal of real estate with amounts exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: None.
- (vii) Information regarding related-parties purchases and/or sales with amounts exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: None.
- (viii) Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: Please refer to schedule F.
- (ix) Information regarding trading in derivative financial instruments: Please refer to Note 6(b).
- (x) Business relationships and significant inter-company transactions: Please refer to schedule G.
- (b) Information on investments: Please refer to schedule H.
- (c) Information on investment in mainland China: Please refer to schedule I.
- (d) Information on major shareholders: Please refer to schedule J.

### (14) Segment information:

(a) General information:

The Group's reportable segment are the foundry segment, and agriculture technology segment. The segments engages separately in researching, developing, manufacturing, selling of GaAs wafers and researching and developing hog farming technology and trading, etc., respectively.

Other operating segments are mainly engaged in investment activities and testing service gene chip, which do not exceed the quantitative thresholds to be reported.

(b) Profit or loss (including reportable segment specific revenue and expenses), segment assets, segment liabilities, and their measurement and reconciliations:

The reportable amount is same as that in the report used by the operating decision maker and the operating segment accounting policies are same as the ones described in Note 4 "significant accounting policies" were as follows:

For the three months ended March 31, 2023		Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue:		_				
Revenue from external customers	\$_	2,516,905	110,438	232,215		2,859,558
Interest expenses	\$	48,510	88,460	1,610		138,580
Depreciation and amortization	\$	921,919	175,887	8,823		1,106,629
Share of profit (loss) of associates and joint ventures accounted for using equity method	<b>\$</b> _	17,724	(33,663)	18,974	-	3,035
Reportable segment profit or loss	\$	(546,063)	(211,615)	162,925		(594,753)
Assets:						
Capital expenditures in non-current assets	\$_	444,332	121,975	4,325		570,632

For the three months ended March 31, 2022		Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue:		rounary	technology	Others	emmation	<u> 10tai</u>
Revenue from external customers	\$_	5,498,479	47,589	50,925		5,596,993
Interest expenses	\$	51,391	27,426	1,684		80,501
Depreciation and amortization	\$	998,583	87,222	8,299		1,094,104
Share of profit (loss) of associates and joint ventures accounted for using equity method	<b>\$</b> _	95,148	(33,693)	20,423		81,878
Reportable segment profit or loss	\$	1,254,271	(326,523)	(11,530)	_	916,218
Assets:	_				-	
Capital expenditures in non-current assets	\$_	658,312	677,451	2,546		1,338,309

For the three months ended March 31, 2023 and 2022, reportable segment profit or loss excludes non-operating income and expenses, amounting to \$39,132 thousand and \$74,544 thousand, respectively.

#### Schedule A Loans to other parties:

(In thousands of Dollars)

Number (Note 1)		Name of borrower	Account name	Related party	Highest balan of financing t other parties du	ing	Ending balance (Note 2)	Actual amount drawn down	Interest rate	Purposes of fund financing for the borrower	Transaction amount	Reasons for short-term financing	Allowance for bad debts		ateral	Individual funding loan limits (Note 4) (Note 5)	Maximum limit of fund financing (Note 4) (Note 5)	Remark
					the period (Note	(2)				(Note 3)				Item	Value	(Note 6)	(Note 6)	
1	Chainwin Biotech and Agrotech	Jiangsu Chainwin Kang Yuan Agricultural	Other receivables	Y	913,	500	913,500	609,000	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 8)
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.			( USD 30,0	00)(	USD 30,000	( USD 20,000 )				Capital				1,765,507	3,531,015	
1	Chainwin Biotech and Agrotech	Jiangsu Win Yield Agriculture	Other receivables	Y	609,	000	-	-	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 8)
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.			( USD 20,0	00)						Capital				1,765,507	3,531,015	
2	Jiangsu Chainwin Agriculture and	Jiangsu Win Shine Agriculture Development	Other receivables	Y	17,	248	17,248	17,248	0%	2	-	Working	-	None	-	Net equity 100%=	Net equity 200%=	(Note 8)
	Animal Technology Co., Ltd.	Co., Ltd.			( RMB 3,8	93)(	( RMB 3,893 )	( RMB 3,893 )				Capital				1,081,435	2,162,871	
3	Jiangsu Win Honor Management	Jiangsu Win Yield Agriculture Development	Other receivables	Y	291,	711	-	-	1%	2	-	Working	-	None	-	Net equity 110%=	Net equity 200%=	(Note 8)
	Technology Co., Ltd.	Co., Ltd.			( USD 9,5	80)						Capital				327,200	594,909	

Note 1: Company numbering as follows:

Issuer-0

Investee starts from 1

Note 2: The credit amount to lending

Note 3: Purposes of lending were as follows:

- 1. Business relationship
- 2. Short-term financing

Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of financing to other parties:

- 1. The loan limit to an individual party:(1) the total amount for lending to a company having business relationship with Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
- (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.
- 2. The maximum loans to other parties limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.

Note 5: Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.'s operating procedures of financing to other parties:

- 1. The loan limit to an individual party:(1) the total amount for lending to a company having business relationship with Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
- (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. 's equity based on its most recent audited or reviewed financial statements by a certified accountant.
- 2. The maximum loans to other parties limit provided by Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. to other parties should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
- 3. The fund lending to Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s non-Taiwan subsidiaries (between subsidiaries) having, directly or indirectly, 100% of the voting rights; or the fund lending to the parent company, Chainwin Biotech and Agrotech (Cayman Islands)

  Co., Ltd., (subsidiary-to-parent), should not be restricted by the above limitations; however, the maximum limit for an individual party should not exceed 100% of Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. 's equity, and the total amount should not exceed 200% of Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.'s equity.

Note 6: Jiangsu Win Honor Management Technology Co., Ltd. 's operating procedures of financing to other parties:

- 1. The loan limit to an individual party: (1) the total amount for lending to a company having business relationship with Jiangsu Win Honor Management Technology Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).

  (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Jiangsu Win Honor Management Technology Co., Ltd.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.
- 2. The maximum loans to other parties provided by Jiangsu Win Honor Management Technology Co., Ltd. should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
- 3. The fund lending to Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s non-Taiwan subsidiaries (between subsidiaries) having, directly, 100% of the voting rights; or the fund lending to the parent company, Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s non-Taiwan subsidiaries (between subsidiaries) having, directly or indirectly, 100% of the voting rights; or the fund lending to the parent company, Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s equity, and the total amount should not exceed 200% of Jiangsu Win Honor Management Technology Co., Ltd.'s equity, and the total amount should not exceed 200% of Jiangsu Win Honor Management Technology Co., Ltd.'s equity.
- Note 7: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD and RMB to USD for TWD 30.45 and USD 0.1455, respectively.
- Note 8: The amount of the transaction had been offset in the consolidated financial statements.

Schedule B Guarantees and endorsements for other parties:

(In thousands of Dollars)

		Counter-party of guarantee and endorser	nent	Limitation on		D			Ratio of				
Number (Note 1)	Name of guarantor	Name	Relationship with the Company (Note 2)	amount of guarantees and endorsements for a specific enterprise (Note 3)(Note 4)	Highest balance of guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 3)(Note 4)	Parent company endorsements/ guarantees to subsidiary (Note 6)	Subsidiary endorsements/ guarantees to parent company (Note 6)	Endorsements/ guarantees to the companies in mainland China (Note 6)
0	The Company	Chainwin Biotech and Agrotech (Cayman	2	16,144,214	1,522,500	1,522,500	1,522,500	-	4.72%	Net equity 50%=	Y	-	-
		Islands) Co., Ltd.								16,144,214			
0	"	Jiangsu Chainwin Kang Yuan Agricultural	2	16,144,214	1,827,000	1,827,000	1,827,000	-	5.66%	Net equity 50%=	Y	-	Y
		Development Co., Ltd.								16,144,214			
0	"	Jiangsu Win Yield Agriculture Development	2	16,144,214	3,349,500	3,349,500	3,349,500	-	10.37%	Net equity 50%=	Y	-	Y
		Co., Ltd.								16,144,214			
0	"	Jiangsu Chainwin Agriculture and Animal	2	16,144,214	1,370,250	1,370,250	1,370,250	-	4.24%	1 ,	Y	-	Y
		Technology Co., Ltd.								16,144,214			
0	"	Jiangsu Win Fortune Agrichture	2	16,144,214	426,300	426,300	-	-	1.32%	Net equity 50%=	Y	-	Y
		Development Co., Ltd.								16,144,214			
0	"	Jiangsu Win Boutique Agriculture	2	16,144,214	319,725	319,725	-	-	0.99%	Net equity 50%=	Y	-	Y
		Development Co. Ltd.								16,144,214			
0	"	Jiangsu Win Sunlight Agriculture	2	16,144,214	319,725	319,725	-	-	0.99%	1 ,	Y	-	Y
		Development Co. Ltd.								16,144,214			
1	Chainwin Biotech and Agrotech	Jiangsu CM/Chainwin Agriculture	6	2,648,261	223,808	223,808	-	-	2.54%		-	-	Y
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.		,	,	( USD 7,350 )				4,413,769			
1	"	Jiangsu Chainwin Kang Yuan Agricultural	2	2,648,261	137,025	54,810	15,957	60,900	0.62%		-	-	Y
		Development Co., Ltd.		( USD 86,971 )	( USD 4,500 )	( USD 1,800 )	(RMB 524)	( USD 2,000 )		4,413,769			

Note 1: Company numbering as follows:

- $1.\ Issuer 0$
- 2. Investee starts from 1

Note 2: The 7 types of relationship between the guarantee and the guarantor were as follows:

- 1. For entities the guarantor has business transaction with.
- 2. For entities in which the guarantor, directly or indirectly, owned more than 50% of their shares.
- 3. For entities who owned, directly or indirectly, more than 50% in total of the guarantor's shares.
- 4. For entities in which the guarantor, directly or indirectly, owned more than 90% of their shares.
- 5. Fulfillment of contractual obligation by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
- 6. For entities who are guaranteed and endorsed by all capital contributing shareholders in proportion to each of their shareholder's percentage.
- 7. Performance guarantee in which entities within the same industry provide among themselves joint and several securities by entering into sales agreement with each other for pre-construction project pursuant to Company Protection Act.

Note 3: WIN Semiconductors Corp.'s operating procedures of guarantee and endorsement were as follows:

- 1. The guarantees and endorsements limit provided by WIN Semiconductors Corp. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
- 2. The guarantees and endorsements limit provided by WIN Semiconductors Corp. and its subsidiaries to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
- 3.WIN Semiconductors Corp. endorses and guarantees the bank debts of its subsidiaries, including Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd., Jiangsu Win Yield Agriculture Development Co., Ltd., Jiangsu Win Fortune Agriculture Development Co., Ltd., Jiangsu Win Boutique Agriculture Development Co. Ltd. and Jiangsu Win Sunlight Agriculture Development Co. Ltd. The total amount of the endorsement guarantee should not exceed US\$300,000 thousand.

Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of guarantee and endorsement were as follows:

- 1. The individual guarantee amount should not exceed 30% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
- 2. The guarantees and endorsements limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
- Note 5: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD and RMB to USD for TWD 30.45 and USD 0.1455, respectively.
- Note 6: Fill in "Y" for those cases of provision of endorsements/ guarantees by listed parent company to subsidiary, provision by subsidiary to listed parent company, and provision to the party in mainland China.

Schedule C Securities held as of March 31, 2023 (excluding investment in subsidiaries, associates and joint ventures):

(In thousands of New Taiwan Dollars)

	G. 1	N 1 2 12			Ending	balance		
Name of holder	Category and name of security	Relationship with the company	Account name	Shares/ Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	Remark
The Company	Lin BioScience, Inc./Stock	None	Current financial assets at fair value through profit or loss	55	10,139	0.08	10,139	
WIN Venture Capital Corp.	Capital Money Market Fund	"	<i>II</i>	3,154	51,820	-	51,820	
WIN Chance Investment Corp.	Capital Money Market Fund	"	<i>II</i>	1,004	16,499	-	16,499	
WIN Earn Investment Corp.	Capital Money Market Fund	"	//	2,635	43,298	-	43,298	
					121,756		121,756	
The Company	MagiCapital Fund II L.P.	"	Non-current financial assets at fair value through profit or loss	-	307,906	5.81	307,906	
//	CDIB Capital Growth Partners L.P.	"	//	-	173,552	3.30	173,552	
"	CDIB Capital Healthcare Ventures II L.P.	"	<i>II</i>	-	45,609	1.61	45,609	
"	Fuh Hwa Oriental Fund	"	<i>II</i>	15,000	26,400	-	26,400	
"	Fuh Hwa Smart Energy Fund	"	<i>II</i>	12,000	86,208	-	86,208	
"	LeaSun Winion L.P.	"	<i>II</i>	-	32,070	12.47	32,070	
"	NFC Fund II L.P.	"	<i>II</i>	-	245,868	32.88	245,868	
"	Foryou Venture Capital L.P.	"	<i>II</i>	-	31,200	5.77	31,200	
"	Renaissance Capital Limited Partnership	"	"	-	116,219	12.82	116,219	
"	Lian Ding Capital Investments Limited Partnership	"	"	-	228,000	10.23	228,000	
"	NFC Fund III, L.P.	"	"	-	107,161	19.90	107,161	
Win Semiconductors Cayman Islands Co., Ltd.	Vanchip (Tianjin) Technology Co., Ltd./Stock	Client	"	1,800	472,590	0.44	472,590	
					1,872,783		1,872,783	1
The Company	Sino-American Silicon Products Inc./Stock	None	Non-current financial assets at fair value through other comprehensive income	529	82,524	0.09	82,524	l
"	Inventec Solar Energy Corporation/Stock	"	"	34,000	-	10.51	-	(Note 1)
"	CDIB Capital Creative Industries Limited/Stock	"	"	3,000	18,360	3.33	18,360	
"	MagiCap Venture Capital Co., Ltd./Preferred Stock A	"	"	543	29,592	18.28	29,592	
"	New Future Capital Co., Ltd./Stock	"	<i>II</i>	8,900	85,529	15.87	85,529	
"	Grand Fortune Venture Corp./Stock	"	<i>II</i>	4,000	43,280	6.87	43,280	
"	NFC I Renewable Power Co., Ltd./Stock	"	<i>II</i>	16,200	324,575	15.00	324,575	
"	Gogolook Co., Ltd./Stock	"	<i>II</i>	3,550	104,082	11.49	104,082	
Win Semiconductors Cayman Islands Co., Ltd.	Broadcom Ltd./Stock	Client	<i>II</i>	75	1,465,117	0.02	1,465,117	
"	Anokiwave Inc./Series B Preferred Stock	"	<i>II</i>	1,264	-	7.48	-	
WIN Venture Capital Corp.	MOAI Green Power Corporation/Stock	None	//	90	-	0.24	-	
"	Merit Biotech INC./Stock	"	//	1,320	-	2.93	-	(Note 2)
"	Winresp INC./Stock	"	//	2,896	43,048	11.71	43,048	
					2,196,107	]	2,196,107	1
						1		1

Note 1: The Board of Directors of Inventee Solar Energy Corporation had declared to bankruptcy the company in December 2021. As of March 31, 2023, the company had not completed the procedure of liquidation.

Note 2: The Board of Directors of Merit Biotech INC. had resolved to dissolve and liquidate the company in 2017. As of March 31, 2023, the company was still within the period of liquidation.

Schedule D Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

	Category and				Relationship		Beginning		Purchases				Sales		Ending	
Name of company	name of security	Account name	Name of counter-party	with the Company	Shares (in thousands)	Amount	Shares (in thousands)	Amount	Shares (in thousands)	Price	Cost	Gain (loss) on disposal	Shares (in thousands)	Amount		
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Win Yield Agriculture	Investments accounted for using equity method	-	Subsidiary	-	2,355,555	-	300,400	-	-	-	-	-	2,280,272		
	Development Co., Ltd.													(Note)		

Note: The amount of ending balance was calculated using the equity method. The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

Schedule E Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Nama of	Name of Name of property Transaction date	Transaction	Status of narment		Relationship		counter-party e the previous			References for	Purpose of				
company	Name of property	Transaction date	amount	Status of payment (		amount		with the Company	Owner	Relationship with the Company	Date of transfer	Amount		acquisition	
The Company	Factory buildings	2021/4/6~2021/5/25			Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None		
и	Factory buildings	2021/10/15			Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None		
"	Factory buildings	2022/6/9			Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None		

Schedule F Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Name of counter-party	Relationship	Ending balance	Turnover rate	Amount	Overdue Action taken	Amounts received in subsequent period	Allowances for bad debts	Remark
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Affiliate	611,280	(Note 1)	-	-	-	-	(Note 2)
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Affiliate	560,455	(Note 1)	-	=	=	-	(Note 2)

Note 1: The ending balance was other receivables, which was not applicable for the calculation of turnover rate.

Note 2: The amount of the transaction had been offset in the consolidated financial statements.

Schedule G Business relationships and significant inter-company transactions:

(In thousands of New Taiwan Dollars)

Г				Nature of							
	Number (Note 1)	Name of company	Name of counter-party	p (Note 2)	Account name	Amount (Note 3)	Trading terms	Percentage of the consolidated net revenue or total assets			
	1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	3	Other receivables due from related parties	611,280	no difference with non-related parties	0.88%			
	2	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	611,280	no difference with non-related parties	0.88%			
	1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	3	Other receivables due from related parties	560,455	no difference with non-related parties	0.81%			
	3	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	560,455	no difference with non-related parties	0.81%			

Note 1: Company numbering as follows:

Parent company — 0 Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary - 1 Subsidiary to parent company - 2

Subsidiary to parent company— Subsidiary to subsidiary—3

Note 3: The amount of the transaction had been offset in the consolidated financial statements.

#### Schedule H Information on investments:

The following is the information on investees as of March 31, 2023 (excluding information on investees in mainland China):

(In thousands of New Taiwan Dollars)

			Main	Original inves	tment amount	The en	ding balance at this pe	Net income	S OI NEW Talv		
Name of investor	Name of investee	Location	businesses and	The ending balance	The ending balance	Shares	Percentage of	Carrying	(losses)	Investment income (losses)	Remark
			products	products at the end at the beginning		(in thousands)	ownership	value	of investee	income (iosses)	
The Company	WIN SEMI. USA, INC.	California USA	Marketing	8,203	8,203	1,000	100.00%	(15,003)	(7,788)	(7,788)	(Note 1)
"	Win Semiconductors Cayman	Cayman Islands	Investment activities	11,127,774	11,127,774	376,600	100.00%	9,314,390	(85,399)	(85,399)	(Note 1)
	Islands Co., Ltd.										
"	WIN Venture Capital Corp.	Taiwan	Investment activities	1,040,000	1,040,000	104,000	100.00%	1,098,993	1,791	1,791	(Note 1)
" 1	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density	1,079,169	1,079,169	53,427	73.67%	497,324	(43,605)	(32,122)	(Note 1)
			gene chips and testing service								
"	WIN Chance Investment Corp.	Taiwan	Investment activities	830,000	830,000	87,350	100.00%	929,358	2,140	2,140	(Note 1)
"	WIN Earn Investment Corp.	Taiwan	Investment activities	580,000	580,000	58,000	100.00%	472,421	1,213	1,213	(Note 1)
"	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	6,120,993	6,120,993	65,409	18.02%	7,876,134	73,983	17,724	
			copper-clad laminates, prepreg, and electronic components								
WIN Venture Capital Corp.	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density	39,600	39,600	1,116	1.54%	27,794	(43,605)	(Note 2)	(Note 1)
			gene chips and testing service								
"	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	952,396	952,396	8,767	2.42%	976,148	73,983	(Note 2)	
			copper-clad laminates, prepreg, and electronic components								
Win Semiconductors Cayman	Rainbow Star Group Limited	British Virgin	Investment activities	62,920	62,920	38	49.30%	57,716	26,744	(Note 2)	
Islands Co., Ltd.		Islands									
"	Chainwin Biotech and Agrotech	Cayman Islands	Investment activities	10,905,959	10,905,959	185,054	81.23%	7,296,477	(351,556)	(Note 2)	(Note 1)
	(Cayman Islands) Co., Ltd.										
Chainwin Biotech and Agrotech	Win Lux Biotech (Cayman Islands)	"	Investment activities	15,010	15,010	500	100.00%	11,542	(25)	(Note 2)	(Note 1)
(Cayman Islands) Co., Ltd.	Co., Ltd.										
" i	i-Chainwin Technology Co., Ltd.	Taiwan	Information software services	220,000	220,000	22,000	100.00%	135,151	(4,072)	(Note 2)	(Note 1)
"	Win Lux Biotech Co., Ltd.	Taiwan	Biotechnology services and pharmaceutical testing	250,000	100,000	25,000	100.00%	152,523	(15,419)	(Note 2)	(Note 1)
Phalanx Biotech Group, Inc.	Phalanx Biotech Limited	Hong Kong	Investment activities	12,125	12,125	-	100.00%	537	(958)	(Note 2)	(Note 1)
"	PhalanxBio, Inc.	USA	Selling of high-density gene chip and testing service	208,110	208,110	2,550	100.00%	19	-	(Note 2)	(Note 1)
	Guzip Biomarkers Corporation	Taiwan	Development and sales of test reagents for endometrial cancer	81,727	81,727	14,238	100.00%	75,854	655	(Note 2)	(Note 1)
WIN Chance Investment Corp.	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	832,945	832,945	7,935	2.19%	912,663	73,983	(Note 2)	
			copper-clad laminates, prepreg, and electronic components								
WIN Earn Investment Corp.	ITEQ Corporation	Taiwan	n .	568,005	568,005	4,230	1.17%	429,234	73,983	(Note 2)	

Note 1: The amount of the transaction had been offset in the consolidated financial statements.

Note 2: The share of profit (loss) of the investee company is not reflected herein as such amount is already included in the share of profit (loss) of the investor company.

Schedule I Information on investment in mainland China:

(i) The names of investees in mainland China, the main businesses and products, and other information:

(In thousands of Dollars)

		I			Α	nulated outflow				1 . 1 .0			Direct/Indirect			C		(In thousands	or Donars)
Name of	Main businesses	Total	amount	Method of		estment from	Investment f	lows		ilated outflow estment from	Net incor	me (losses)	percentage of		stment		ring value the end	Accumulated remittance of	
investee	and products		-in capital	investment		iwan at the	III Common 1	.0115		wan at the		investee	ownership by the		e (losses)		is period	earnings in current	Remark
	*		*		beginn	ing of this year	Outflow	Inflow		h 31, 2023			Company	(Note 5	)(Note 7)		lote 6)	period	
Jiangsu Chainwin Kang Yuan	Developing hog farming technology		3,728,267	(Note 1)		3,309,022	-	-		3,309,022		(65,100)	81.23%		(65,100)		2,170,350	-	(Note 11)
Agricultural Development Co., Ltd.	and trading	(RMB	847,767)		( USD	113,043 )			( USD	113,043)	(USD	(2,165))		(USD	(2,165))	( USD	71,276)		
Jiangsu Chainwin Agriculture and	Farm feed developing and trading		1,314,369	(Note 1)		1,291,505	-	-		1,291,505		(27,606)	81.23%		(27,606)		1,081,436	-	(Note 11)
Animal Technology Co., Ltd.		( USD	43,790)		( USD	43,046)			( USD	43,046)	(USD	(914))		(USD	(914))	( USD	35,515)		
Jiangsu CM/Chainwin Agriculture	Developing hog farming technology	1	2,059,210	(Note 1)		1,122,874	-	_	1	1,122,874	,	(68,700)	39.80%		(33,663)		654,216	-	
Development Co., Ltd.	and trading	( USD	67,584)		( USD	36,821)			( USD	36,821)	(USD	(2,259))		(USD	(1,107))	( USD	21,485)		
Jiangsu Win Chance Agriculture	Developing hog farming technology	1	610,094	(Note 1)		651,142	-	_	1	651,142	,	(7,081)	81.23%		(7,081)		291,005	-	(Note 11)
Development Co., Ltd.	and trading	( USD	20,200)		( USD	21,569)			( USD	21,569)	(USD	(231))		(USD	(231))	( USD	9,557)		
Jiangsu Merit/Cofcojoycome	Developing hog farming technology		- 1	(Note 1)		149,664	-	-		149,664		-	-		-		-	-	(Note 9)
Agriculture Development Co., Ltd.	and trading				( USD	4,872)			( USD	4,872)									
Jiangsu Merit Runfu Agriculture	Developing hog farming technology		72,313	(Note 3)		41,009	-	_		41,009		4	81.23%		4		8,380	-	(Note 11)
Development Co., Ltd.	and trading	(RMB	16,177)		( USD	1,335)			( USD	1,335)	( RMB	1)		(RMB	1)	( RMB	1,891)		
Jiangsu Win Yield Agriculture	Developing hog farming technology		2,655,955	(Note 1)		2,160,535	300,400	_		2,460,935		(65,958)	81.23%		(65,958)		2,280,272	-	(Note 11)
Development Co., Ltd.	and trading	( USD	91,500)		( USD	74,500)	(USD 10,000)		( USD	84,500)	(USD	(2,196))		(USD	(2,196))	( USD	74,886)		
Jiangsu Win Shine Agriculture	Logistics management service	1	345,130	(Note 1)		85,170	- 1	_	1	85,170	,	(6,373)	81.23%		(6,373)		316,055	-	(Note 11)
Development Co., Ltd.		( USD	12,000)		( USD	3,000)			( USD	3,000)	(USD	(210))		(USD	(210))	( USD	10,379)		
Jiangsu Win Boutique Agriculture	Developing hog farming technology		288,100	(Note 4)		-	-	-		-		(15,489)	81.23%		(15,489)		256,850	-	(Note 11)
Development Co., Ltd.	and trading	( USD	10,000)								(RMB	(3,458))		(RMB	(3,458))	(RMB	57,973)		
Jiangsu Win Sunlight Agriculture	Developing hog farming technology		288,100	(Note 1)		86,430	-	-		86,430		(3,855)	81.23%		(3,855)		264,696	-	(Note 11)
Development Co., Ltd.	and trading	( USD	10,000)		( USD	3,000)			( USD	3,000)	(USD	(124))		(USD	(124))	( USD	8,693)		
Jiangsu Win Honor Management	Logistics management service		288,100	(Note 4)		_	-	_		-		(3,807)	81.23%		(3,807)		297,455	-	(Note 11)
Technology Co., Ltd.		( USD	10,000)								(RMB	(838))		(RMB	(838))	(RMB	67,138)		
Jiangsu Win Wonder Agriculture	Developing farming technology		88,173	(Note 3)		-	-	-		-		(3,442)	81.23%		(3,442)		73,893	-	(Note 11)
Development Co., Ltd.	and trading	(RMB	20,000)								(RMB	(775))		(RMB	(775))	( RMB	16,678)		
Jiangsu Win Fortune Agriculture	Developing hog farming technology		276,400	(Note 1)		221,120	-	-		221,120		(3,978)	81.23%		(3,978)		285,200	-	(Note 11)
Development Co., Ltd.	and trading	( USD	10,000)		( USD	8,000)			( USD	8,000)	(USD	(128))		(USD	(128))	( USD	9,366)		
Chainwin (Huaian) AIoT Co., Ltd.	Information software services		27,860	(Note 4)		27,860	-	-		27,860		(2,225)	81.23%		(2,225)		24,407	-	(Note 11)
		( USD	1,000)		( USD	1,000)			( USD	1,000)	(RMB	(497))		(RMB	(497))	(RMB	5,509)		
Jiangsu Win Advance Bio-Assay Co., Ltd.	Biotechnology testing service		111,560	(Note 1)		-	-	-		-		(653)	81.23%		(653)		108,320	-	(Note 11)
		( USD	4,000)								(USD	(21))		(USD	(21))	( USD	3,557)		
Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and		27,680	(Note 1)		27,680	-	-		27,680		(387)	81.23%		(387)		29,236	-	(Note 11)
	bioassay	( USD	1,000)		( USD	1,000)			( USD	1,000)	(USD	(12))		(USD	(12))	( USD	960)		
Onearray Biotech (Kunshan) Co., Ltd.	Selling of high density gene chip		12,125	(Note 2)		12,125	-	-		12,125		(958)	75.21%		(958)		561	-	(Note 11)
	and testing service	(RMB	2,663)		( USD	420)			( USD	420)	(RMB	(215))		(RMB	(215))	( RMB	127)		
	<u> </u>															1			

#### (ii) Limitation on investment in mainland China:

#### (In thousands of Dollars)

Investor Company	Accumulated Investment in mainland	Investment Amounts Authorized by	Upper Limit on Investment		
Name	China at the end (Note 8)(Note 9)	Investment Commission, MOEA	(Note 10)		
The Company and subsidiaries	9,747,956 (USD 330,989)	10,721,257 (USD 352,094)	20,453,178		

- Note 1: The Group invested in mainland China companies through Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., which is established in a third region.
- Note 2: The Group invested in mainland China companies through Phalanx Biotech Limited, which is established in a third region.
- Note 3: The Company invested in mainland China companies through Jiansu Win Chance Agriculture Development Co., Ltd.
- Note 4: The Company invested in mainland China companies through Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.
- Note 5: The amount of net income (losses) was recognized based on the reviewed financial statements of the investee companies.
- Note 6: Carrying value as of March 31, 2023 was with reference to the amount recognized by the investment through subsidiaries to subsidiaries established in a third region.
- Note 7: Investment income (loss) recognized was translated into New Taiwan Dollars at the average exchange rate for the each month from January 1 to March 31, 2023.
- Note 8: The Group acquired Vanchip (Tianjin) Technology Co., Ltd. through a third region, wherein the outflow of investment from Taiwan amounted US\$9,383 thousand (NT\$261,420 thousand).
- Note 9: Jiansu Merit/Cofcojoycome Agriculture Development Co., Ltd. had been liquidated on January 25, 2019. However, according to the regulation of Investment Commission the remittance to mainland China amounting to US\$4,872 thousand (NT\$149,664 thousand) was included in the accumulated investment account.
- Note10: Amount of upper limit on investment was the higher between sixty percentage of total equity or total consolidated equity.
- Note11: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.
  - (iii) Significant transactions: Please refer Schedule A, Schedule B, Schedule D, Schedule F, and Schedule G.

#### Schedule J Information on major shareholders:

(In shares)

Shareholding Shareholder's Name	Shares	Percentage
Cathay Life Insurance Co., Ltd.	23,321,000	5.50%